+

WO2012112350A2 - Compositions dentaires comprenant un agent de fragmentation d'addition éthyléniquement insaturé - Google Patents

Compositions dentaires comprenant un agent de fragmentation d'addition éthyléniquement insaturé Download PDF

Info

Publication number
WO2012112350A2
WO2012112350A2 PCT/US2012/024222 US2012024222W WO2012112350A2 WO 2012112350 A2 WO2012112350 A2 WO 2012112350A2 US 2012024222 W US2012024222 W US 2012024222W WO 2012112350 A2 WO2012112350 A2 WO 2012112350A2
Authority
WO
WIPO (PCT)
Prior art keywords
dental composition
dental
monomer
meth
ethylenically unsaturated
Prior art date
Application number
PCT/US2012/024222
Other languages
English (en)
Other versions
WO2012112350A3 (fr
Inventor
Guy D. Joly
Larry R. Krepski
Babu N. Gaddam
Ahmed S. Abuelyaman
Bradley D. Craig
Timothy D. Dunbar
Chuntao Cao
Joel D. Oxman
Afshin Falsafi
William H. Moser
Hoa T. Bui
Original Assignee
3M Innovative Properties Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Company filed Critical 3M Innovative Properties Company
Priority to CN201280008646.3A priority Critical patent/CN103370041B/zh
Priority to JP2013553505A priority patent/JP6077463B2/ja
Priority to RU2013136505/15A priority patent/RU2573997C2/ru
Priority to BR112013019702-1A priority patent/BR112013019702B1/pt
Priority to US13/978,557 priority patent/US9056043B2/en
Priority to EP15175714.3A priority patent/EP2965742B1/fr
Priority to EP12704603.5A priority patent/EP2675422B1/fr
Publication of WO2012112350A2 publication Critical patent/WO2012112350A2/fr
Publication of WO2012112350A3 publication Critical patent/WO2012112350A3/fr
Priority to US14/707,096 priority patent/US9320685B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
    • A61K6/61—Cationic, anionic or redox initiators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/30—Compositions for temporarily or permanently fixing teeth or palates, e.g. primers for dental adhesives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/40—Primers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/884—Preparations for artificial teeth, for filling teeth or for capping teeth comprising natural or synthetic resins
    • A61K6/887—Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds

Definitions

  • compositions having improved properties such as reduced stress deflection and/or reduced shrinkage while maintaining sufficient mechanical properties and depth of cure.
  • a dental composition comprising an addition- fragmentation agent comprising at least one ethylenically unsaturated terminal group and a backbone unit comprising an ⁇ , ⁇ - unsaturated carbonyl; at least one monomer comprising at least two ethylenically unsaturated group; and inorganic oxide filler.
  • the addition-fragmentation agent is preferably free-radically cleavable.
  • the addition- fragmentation agent preferably comprises at least two ethylenically unsaturated terminal groups, such as meth)acrylate groups.
  • the addition- fragmentation agent has the formula:
  • R 1 , R 2 and R 3 are each independently Z m -Q-, a (hetero)alkyl group or a (hetero)aryl group with the proviso that at least one of R 1 , R 2 and R 3 is Z m -Q-;
  • Q is a linking group have a valence of m +1 ;
  • Z is an ethylenically unsaturated polymerizable group
  • n 1 to 6;
  • each X 1 is independently -O- or -NR 4 -, where R 4 is H or C 1 -C4 alkyl;
  • n 0 or 1.
  • a dental article comprising a hardenable dental composition comprising an addition- fragmentation agent as described herein at least partially hardened.
  • methods of treating a tooth surface are described.
  • the method comprises providing a hardenable dental composition comprising an addition- fragmentation agent as described herein; placing the dental composition on a tooth surface in the mouth of a subject; and hardening the hardenable dental composition.
  • the method comprising providing an at least partially hardened dental article comprising an addition- fragmentation agent as described herein, and adhering the dental article on a tooth surface in the mouth of a subject.
  • Figure 1 depicts a machined aluminum block utilized as a sample holder for a curable composition during Stress Deflection testing.
  • Figure 2 depicts a Stress Deflection testing apparatus. Detailed Description
  • dental composition refers to a material, optionally comprising filler, capable of adhering or being bonded to an oral surface.
  • a curable dental composition can be used to bond a dental article to a tooth structure, form a coating (e.g., a sealant or varnish) on a tooth surface, be used as a restorative that is placed directly into the mouth and cured in-situ, or alternatively be used to fabricate a prosthesis outside the mouth that is subsequently adhered within the mouth.
  • Curable dental compositions include, for example, adhesives (e.g., dental and/or orthodontic adhesives), cements (e.g., resin-modified glass ionomer cements, and/or orthodontic cements), primers (e.g., orthodontic primers), liners (applied to the base of a cavity to reduce tooth sensitivity), coatings such as sealants (e.g., pit and fissure), and varnishes; and resin restoratives (also referred to as direct composites) such as dental fillings, as well as crowns, bridges, and articles for dental implants.
  • adhesives e.g., dental and/or orthodontic adhesives
  • cements e.g., resin-modified glass ionomer cements, and/or orthodontic cements
  • primers e.g., orthodontic primers
  • liners applied to the base of a cavity to reduce tooth sensitivity
  • coatings such as sealants (e.g., pit and fissure), and varnishes
  • resin restoratives also
  • Dental cements are somewhat less filled and less viscous materials than composites, and typically act as a bonding agent for additional materials, such as inlays, onlays and the like, or act as the filling material itself if applied and cured in layers. Dental cements are also used for permanently bonding dental restorations such as a crown or bridge to a tooth surface or an implant abutment.
  • dental article refers to an article that can be adhered (e.g., bonded) to a tooth structure or dental implant.
  • Dental articles include, for example, crowns, bridges, veneers, inlays, onlays, fillings, orthodontic appliances and devices.
  • orthodontic appliance refers to any device intended to be bonded to a tooth structure, including, but not limited to, orthodontic brackets, buccal tubes, lingual retainers, orthodontic bands, bite openers, buttons, and cleats.
  • the appliance has a base for receiving adhesive and it can be a flange made of metal, plastic, ceramic, or combinations thereof.
  • the base can be a custom base formed from cured adhesive layer(s) (i.e. single or multi-layer adhesives).
  • oral surface refers to a soft or hard surface in the oral environment.
  • Hard surfaces typically include tooth structure including, for example, natural and artificial tooth surfaces, bone, and the like.
  • hardenable and “curable' is descriptive of a material or composition that can be cured (e.g., polymerized or crosslinked) by heating to induce polymerization and/or crosslinking; irradiating with actinic irradiation to induce polymerization and/or crosslinking; and/or by mixing one or more
  • Mating can be performed, for example, by combining two or more parts and mixing to form a homogeneous composition. Alternatively, two or more parts can be provided as separate layers that intermix (e.g., spontaneously or upon application of shear stress) at the interface to initiate polymerization.
  • hardened refers to a material or composition that has been cured (e.g., polymerized or crosslinked).
  • hardener refers to something that initiates hardening of a resin.
  • a hardener may include, for example, a polymerization initiator system, a photoinitiator system, a thermal initiator and/or a redox initiator system.
  • (meth)acrylate is a shorthand reference to acrylate, methacrylate, or combinations thereof;
  • (meth)acrylic is a shorthand reference to acrylic, methacrylic, or combinations thereof.
  • (meth)acryl is a shorthand reference to acryl, methacryl, or combinations thereof.
  • acryloyl is used in a generic sense and mean not only derivatives of acrylic acid, but also amine, and alcohol derivatives, respectively;
  • (meth)acryloyl includes both acryloyl and methacryloyl groups; i.e. is inclusive of both esters and amides.
  • alkyl includes straight-chained, branched, and cyclic alkyl groups and includes both
  • alkyl groups typically contain from 1 to 20 carbon atoms.
  • alkyl as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, isobutyl, t-butyl, isopropyl, n-octyl, n-heptyl, ethylhexyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, and norbornyl, and the like.
  • alkyl groups may be mono- or polyvalent, i.e monvalent alkyl or polyvalent alkylene.
  • heteroalkyl includes both straight-chained, branched, and cyclic alkyl groups with one or more heteroatoms independently selected from S, O, and N with both unsubstituted and substituted alkyl groups. Unless otherwise indicated, the heteroalkyl groups typically contain from 1 to 20 carbon atoms. "Heteroalkyl” is a subset of “hydrocarbyl containing one or more S, N, O, P, or Si atoms" described below.
  • heteroalkyl examples include, but are not limited to, methoxy, ethoxy, propoxy, 3,6-dioxaheptyl, 3-(trimethylsilyl)-propyl, 4-dimethylaminobutyl, and the like. Unless otherwise noted, heteroalkyl groups may be mono- or polyvalent, i.e. monovalent heteroalkyl or polyvalent heteroalkylene.
  • aryl is an aromatic group containing 6-18 ring atoms and can contain optional fused rings, which may be saturated, unsaturated, or aromatic.
  • Examples of an aryl groups include phenyl, naphthyl, biphenyl, phenanthryl, and anthracyl.
  • Heteroaryl is aryl containing 1 -3 heteroatoms such as nitrogen, oxygen, or sulfur and can contain fused rings.
  • Some examples of heteroaryl groups are pyridyl, furanyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl, benzofuranyl, and benzthiazolyl.
  • aryl and heteroaryl groups may be mono- or polyvalent, i.e. monovalent aryl or polyvalent arylene.
  • (hetero)hydrocarbyl is inclusive of hydrocarbyl alkyl and aryl groups, and heterohydrocarbyl heteroalkyl and heteroaryl groups, the later comprising one or more catenary oxygen heteroatoms such as ether or amino groups.
  • Heterohydrocarbyl may optionally contain one or more catenary (in-chain) functional groups including ester, amide, urea, urethane, and carbonate functional groups. Unless otherwise indicated, the non-polymeric (hetero)hydrocarbyl groups typically contain from 1 to 60 carbon atoms.
  • heterohydrocarbyls as used herein include, but are not limited to, methoxy, ethoxy, propoxy, 4-diphenylaminobutyl, 2-(2'-phenoxyethoxy)ethyl, 3,6-dioxaheptyl, 3,6- dioxahexyl-6-phenyl, in addition to those described for "alkyl”, “heteroalkyl", “aryl”, and “heteroaryl” supra.
  • the dental composition comprises at least one addition-fragmentation agent.
  • the addition-fragmentation agent comprising at least one ethylenically unsaturated terminal group and a backbone unit comprising an ⁇ , ⁇ - unsaturated carbonyl.
  • the addition-fragmentation agent is free-radically cleavable.
  • addition-fragation agents are preferably of the following formula:
  • R 1 , R 2 and R 3 are each independently Z m -Q-, a (hetero)alkyl group or a (hetero)aryl group with the proviso that at least one of R 1 , R 2 and R 3 is Z m -Q-,
  • Q is a linking group have a valence of m +1 ;
  • Z is an ethylenically unsaturated polymerizable group
  • n 1 to 6, preferably 1 to 2;
  • each X 1 is independently -O- or -NR 4 -, where R 4 is H or C1-C4 alkyl, and
  • n 0 or 1.
  • Addition-fragmentation agents according to Formula I are described in U.S. provisional patent application 61/442980, concurrently filed February 15, 201 1 ; incorporated herein by reference.
  • the addition- fragmentation materials may be added to a dental composition comprising at least one ethylenically unsaturated monomer or oligomer.
  • the inclusion of such addition- fragmentation material reduces the polymerization-induced stresses, such as by the mechanism described in U.S. provisional patent application 61/442980.
  • the material can function as crosslinking agents, where the crosslinks are labile.
  • the ethylenically unsaturated moiety, Z, of the monomer may include, but is not limited to the following structures, including (meth)acryloyl, vinyl, styrenic and ethynyl, that are more fully described in reference to the preparation of the compounds below.
  • R is H or C 1 -C4 alkyl.
  • Q is selected from -0-, -S-, -NR 4 -, -S0 2 -, -P0 2 -, -CO-, -0C0-, -R 6 - , - NR 4 -CO- NR 4 -, NR 4 -CO-0-, NR 4 -CO-NR 4 -CO-0-R 6 -, -CO-NR 4 -R 6 -, -R 6 -CO-0-R 6 -, -0-R 6 -.
  • each R 4 is hydrogen, a d to C 4 alkyl group, or aryl group
  • each R 6 is an alkylene group having 1 to 6 carbon atoms, a 5- or 6-membered cycloalkylene group having 5 to 10 carbon atoms, or a divalent arylene group having 6 to 16 carbon atoms, with the proviso that Q-Z does not contain peroxidic linkages.
  • Q is an alkylene, such as of the formula -C r H 2r -, where r is 1 to 10. In other embodiments, Q is a hydroxyl-substituted alkylene, such as -CH 2 -CH(OH)-CH 2 -. In some embodiments, Q is an aryloxy-substituted alkylene. In some embodiments, R 5 is an alkoxy-substituted alkylene.
  • the compounds of Formula I may be prepared from (meth)acrylate dimers and trimers by substitution, displacement or condensation reactions.
  • the starting (meth)acrylate dimers and trimers may be prepared by free radical addition of a (meth)acryloyl monomer in the presence of a free radical initiator and a Cobalt (II) complex catalyst using the process of U.S.
  • the (meth)acryloyl dimers and trimers may be prepared using a cobalt chelate complex using the processes of U.S. 4,886,861 (Janowicz) or U.S. 5,324,879 (Hawthorne), incorporated herein by reference.
  • the reaction mixture can contain a complex mixture of dimers, trimers, higher oligomers and polymers and the desired dimer or trimer can be separated from the mixture by distillation.
  • Such synthesis is further described in U.S. provisional patent application 61/442980 and the forthcoming examples.
  • concentration of a component of hardenable (i.e. polymerizable) dental composition described herein can be expressed with respect to the (i.e. unfilled) polymerizable resin portion of the dental composition.
  • concentration of monomer can also be expressed with respect to the total (i.e. filled) composition.
  • the polymerizable resin portion is the same as the total composition.
  • the polymerizable resin portion of the hardenable (i.e. polymerizable) dental composition described herein comprises at least 0.5 wt-%, or 1 wt-%, 1.5 wt-%, or 2 wt-% of addition- fragmentation agent(s).
  • the addition- fragmentation agent may comprise a single monomer or a blend of two or more addition- fragmentation agents.
  • the total amount of addition-fragmentation agent(s) in the polymerizable resin portion of the hardenable (i.e. polymerizable) dental composition is typically no greater than 30 wt- %, 25 wt-%, 20 wt-%, or 15 wt-%.
  • the inclusion of the addition- fragmentation agent(s) provides a significant reduction in stress even though the stress deflection is greater than 2.0 microns.
  • the inclusion of the addition- fragmentation agent(s) may reduce the stress from about 7 microns to about 6, or about 5, or about 4, or about 3 microns.
  • the total amount of addition- fragmentation agent(s) in the polymerizable resin portion of the hardenable (i.e. polymerizable) dental composition is no greater than 14 wt-%, 13 wt- %, or 12 wt-%, or 1 1 wt-%, or 10 wt-%.
  • addition- fragmentation agent(s) typically comprises at least 0.1 wt-%, or 0.15 wt-%, or 0.20 wt-% of addition- fragmentation agent(s).
  • the total amount of addition- fragmentation agent(s) in the filled hardenable (i.e. polymerizable) dental composition is typically no greater than 5 wt-%, or 4 wt-%, or 3 wt-%, or 2 wt-%.
  • the hardenable (e.g. dental) compositions described herein further comprise at least one ethylemcally unsaturated monomer or oligomer in combination with the addition- fragmentation agent.
  • the ethylemcally unsaturated monomer may be monofunctional, having a single (e.g. terminal) ethylemcally unsaturated group.
  • the ethylemcally unsaturated monomer is multifunctional.
  • multifunctional ethylemcally unsaturated means that the monomers each comprise at least two ethylemcally unsaturated (e.g. free radically) polymerizable groups, such as (meth)acrylate groups.
  • H 2 C CH(CH 3 )CON-) and (meth)acrylate(CH 2 CHCOO- and CH 2 C (CH 3 )COO-).
  • the ethylemcally unsaturated terminal polymerizable group(s) is preferably a (meth)acrylate group, particularly for compositions that are hardened by exposure to actinic (e.g. UV) radiation. Further, methacrylate functionality is typically preferred over the acrylate functionality in curable dental compositions.
  • the ethylemcally unsaturated monomer may comprise various ethylemcally unsaturated monomers, as known in the art, for use in dental compositions.
  • the (e.g. dental) composition comprises one or more ethylemcally unsaturated (e.g. (meth)acrylate) monomers having a low volume shrinkage monomer.
  • Preferred (e.g. filled) dental compositions (useful for restorations such as fillings and crowns) described herein comprise one or more low volume shrinkage monomers such that the composition exhibits a Watts Shrinkage of less than about 2%. In some embodiments, the Watts Shrinkage is no greater than 1.90%, or no greater than 1.80%, or no greater than 1.70%, or no greater than 1.60%.
  • the Watts Shrinkage is no greater than 1.50%, or no greater than 1.40%, or no greater than 1.30%, and in some embodiments no greater than 1.25%, or no greater than 1.20%, or no greater than 1.15%, or no greater than 1.10%.
  • Preferred low volume shrinkage monomers include isocyanurate monomers, such as described in WO201 1/126647; tricyclodecane monomers, such as described in EP Application No. 10168240.9, filed July 02, 2010; polymerizable compounds having at least one cyclic allylic sulfide moiety such as described in US2008/0194722; methylene dithiepane silanes as described in US 6,794,520; oxetane silanes such as described in US 6,284,898; and di-, tri, and/or tetr-(meth)acryloyl-containing materials such as described in WO2008/082881 ; each of which are incorporated herein by reference.
  • the majority of the (e.g. unfilled) polymerizable resin composition comprises one or more low volume shrinkage monomers.
  • the (e.g. unfilled) polymerizable resin composition comprises one or more low volume shrinkage monomers.
  • at least 50%, 60%, 70%, 80%, 90% or more of the (e.g. unfilled) polymerizable resin may comprise low volume shrinkage monomer(s).
  • the dental composition comprises at least one isocyanurate monomer.
  • the isocyanurate monomer generally comprises a trivalent isocyanuric acid ring as an isocyanurate core structure and at least two ethylenically unsaturated (e.g. free radically) polymerizable groups bonded to at least two of the nitrogen atoms of the isocyanurate core structure via a (e.g. divalent) linking group.
  • the linking group is the entire chain of atoms between the nitrogen atom of the isocyanurate core structure and the terminal ethylenically unsaturated group.
  • the ethylenically unsaturated (e.g. free radically) polymerizable groups are generally bonded to the core or backbone unit via a (e.g. divalent) linking group.
  • the trivalent isocyanurate core structure generally has the formula:
  • the divalent linking group comprises at least one nitrogen, oxygen or sulfur atom.
  • nitrogen, oxygen or sulfur atom forms an urethane, ester, thioester, ether, or thioether linkage.
  • Ether and especially ester linkages can be beneficial over isocyanurate monomers comprising urethane linkages for providing improved properties such as reduced shrinkage, and/or increased mechanical properties, e.g., diametral tensile strength (DTS).
  • DTS diametral tensile strength
  • the divalent linking groups of the iscosyanurate monomer are free of urethane linkages.
  • the divalent linking group comprises an ester linkage such as an aliphatic or aromatic diester linkage.
  • the isocyanurate monomer typically has the general structure
  • R is a straight chain, branched or cyclic alkylene, arylene, or alkarylene, optionally including a heteroatom (e.g. oxygen, nitrogen, or sulfur);
  • R 2 is hydrogen or methyl;
  • Z is alkylene, arylene, or alkarylene linking group comprising at least one moiety selected from urethane, ester, thioester, ether, or thioether, and combinations of such moieties; and at least one of R 3 or R4 is
  • Ri is typically a straight chain, branched or cyclic alkylene, optionally including a heteroatom, having no greater than 12 carbons atoms. In some favored embodiments, Ri has no greater than 8, 6, or 4 carbon atoms. In some favored embodiments, Ri comprises at least one hydroxyl moiety.
  • Z comprises an aliphatic or aromatic ester linkage such as a diester linkage.
  • Z further comprises one or more ether moieties.
  • the linking group may comprise a combination of ester or diester moieties and one or more ether moieties.
  • R 3 or R4 is hydrogen, alkyl, aryl, or alkaryl, optionally including a heteroatom.
  • Ri is generally derived from the starting (e.g. hydroxy terminated) isocyanurate precursor.
  • isocyanurate precursor materials are commercially available from TCI America, Portland, OR.
  • the structures of exemplary isocyanurate precursor materials are depicted as follows:
  • the isocyanurate (meth)acrylate monomers disclosed herein having a linking groups comprising an oxygen atom of an ester moiety were generally prepared by reaction of hydroxy or epoxy terminated isocyanurates with (meth)acrylated carboxylic acids such as mono-(2-methacryloxyethyl)phthalic acid and mono-(2-methacryloxytheyl)succinic acid.
  • Suitable (meth)acrylated carboxylic acids include for example mono-(2- methacryloxyethyl)phthalic acid(s), mono-(2-methacryloxytheyl)succinic acid, and mono-(2- methacryloxyethyl)maleic acid.
  • the carboxylic acid may comprise (meth)acrylamido functionally such as methacrylamido derivatives of naturally occurring amino acids such as
  • methacrylamidoglycine methacrylamidoleucine, methacrylamidoalanine etc.
  • a single(meth)acrylated carboxylic acid is reacted with a single hydroxyl terminated isocyanurate (e.g. tris-(2-hydroxylethyl)isocyanurate).
  • a single hydroxyl terminated isocyanurate e.g. tris-(2-hydroxylethyl)isocyanurate.
  • a sufficient molar ratio of (meth)acrylate carboxylic acid is utilized such that all the hydroxyl groups of the ring are reacted, such synthesis can produce a single reaction product wherein each of the free radically terminated groups, bonded to the nitrogen atoms of the trivalent isocyanuric acid ring, are the same.
  • the reaction product generally comprises more than one isomer in the reaction product.
  • (meth)acrylated) carboxylic acids are utilized, a statistical mixture of reaction products are obtained based on the relative amounts of reactants. For example, when a mixture of a (meth)acrylated aromatic carboxylic acid and a (meth)acrylate aliphatic carboxylic acid are utilized, some of the free radically terminated divalent linking groups bonded to the nitrogen atom of the trivalent isocyanuric acid ring comprise an aromatic group, whereas others do not. Further, when a combination (e.g. 1 equivalent) of a hydroxyl terminated carboxylic acid and (e.g.
  • a monocarboxylic acid such as octanoic acid
  • a single hydroxyl terminated isocyanurate e.g. tris-(2-hydroxylethyl)isocyanurate
  • a mono(meth)acrylate isocyanurate can be prepared as further described in WO201 1/126647.
  • Such mono(meth)acrylate isocyanurate is suitable for use as a reactive diluent.
  • isocyanurate (meth)acrylate monomers having ether group containing linking groups can be synthesized. For example, in one illustrative synthesis,
  • phthalic acid anhydride can be reacted with a mono-methacrylated di, tri, tetra or polyethylenegylcol in the presence of a catalytic amount of 4-(dimethylamino)pyridine (DMAP) and butylated hydroxytoluene inhibitor (BHT) at 95°C for a 3-6 hours to form a mono-methaycrylated polyethyleneglycol phthalic acid mono-ester.
  • DMAP 4-(dimethylamino)pyridine
  • BHT butylated hydroxytoluene inhibitor
  • the obtained methacrylated acid can be reacted, in acetone, with tris-(2- hydroxyethyl)isocyanurate using dicyclohexyl carbodiimide (DCC ) at 0-5°C then at room temperature.
  • DCC dicyclohexyl carbodiimide
  • tris(2-hydroxyethyl)isocyanurate can be reacted with ethylene oxide to form a polyethylene glycol terminated with a hydroxyl group.
  • the OH termini can be esterified with meth(acrylic) acid to provide a product where the linking group is a polyether.
  • the isocyanurate monomer is preferably a multi(meth)acrylate such as a di(meth)acrylate isocyanurate monomer or a tri(meth)acrylate isocyanurate monomer.
  • the di(meth)acrylate monomer has the general structure:
  • R3 and Z are as previously described;
  • Re is a straight chain, branched, or cyclic alkylene, arylene, or alkarylene, optionally including a heteroatom (e.g. oxygen, nitrogen, or sulfur);
  • Y is alkylene, arylene, or alkarylene linking group comprising at least one moiety selected from urethane, ester, thioester, ether, or thioether, and combinations of such moieties.
  • Illustrative di(meth) aery late isocyanurate monomers includes:
  • the tri(meth)acrylate monomer has the general structure:
  • Ri, R 5 , and R ⁇ are independently a straight chain, branched, or cyclic alkylene, arylene, or alkarylene, optionally including a heteroatom (e.g. oxygen, nitrogen, or sulfur);
  • R 2 is hydrogen or methyl;
  • X, Y, and Z are independently alkylene, arylene, or alkarylene linking group comprising at least one moiety selected from urethane, ester, thioester, ether, thioether, or combinations of such moieties; and R 2 is hydrogen or methyl.
  • Ri, R 5 , and 5 comprise at least one hydroxyl moiety.
  • Illustrative tri(meth)acrylate isocyanurate monomers include for example:
  • the polymerizable resin portion of the hardenable unfilled dental composition described herein may comprise at least 10 wt-%, 15 wt-%, 20 wt-%, or 25 wt-%, multifunctional ethylenically unsaturated isocyanurate monomer(s).
  • the isocyanurate monomer may comprise a single monomer or a blend of two or more isocyanurate monomers.
  • the total amount of isocyanurate monomer(s) in the unfilled polymerizable resin portion of the hardenable (i.e. polymerizable) dental composition is typically no greater than 90 wt-%, 85 wt-%, 80 wt-%, or 75 wt-%.
  • the total amount of isocyanurate monomer(s) in the hardenable unfilled dental composition is at least 30 wt-%, 35 wt-%, or 40 wt-% and no greater than 70 wt-%, 65 wt-%, or 60 wt-%.
  • the total amount of isocyanurate monomer(s) of the filled hardenable (i.e. polymerizable) dental composition is typically no greater than 20 wt-%, or 19 wt-%, or 18 wt-%, or 17 wt-%, or 16 wt-%, or 15 wt-%.
  • the dental composition comprises at least one tricyclodecane monomer.
  • the tricyclodecane monomer may comprise a single monomer or a blend of two or more tricyclodecane monomers.
  • the concentration of multifunctional ethylenically unsaturated tricyclodecane monomer in the (i.e. unfilled) polymerizable resin portion or filled hardenable (i.e. polymerizable) composition can be the same as just described for the multifunctional ethylenically unsaturated isocyanurate monomer.
  • the composition comprises a multifunctional ethylenically unsaturated isocyanurate monomer and multifunctional ethylenically unsaturated tricyclodecane monomer at a weight ratio ranging from about 1.5: 1 to 1 : 1.5.
  • Tricyclodecane monomers generally have the core structure (i.e. backbone unit (U):
  • the tricyclodecane monomers generally have the core structure (i. backbone unit (U):
  • Such tricyclodecane monomers can be prepared for example from starting materials such as
  • the backbone unit (U) typically comprises one or two spacer unit(s) (S) bonded to the backbone unit (U) via an ether linkage.
  • At least one spacer unit (S) comprises a CH(Q)-OG chain, wherein each group G comprises a (meth)acrylate moiety and Q comprises at least one group selected from hydrogen, alkyl, aryl, alkaryl and combinations thereof.
  • Q is hydrogen, methyl, phenyl, phenoxymethyl, and combinations thereof.
  • G may be bonded to the spacer unit(s) (S) via a urethane moiety.
  • the spacer unit(s) (S) typically comprise wherein m is 1 to 3; n is 1 to 3; and Q is hydrogen, methyl, phenyl, phenoxymethyl.
  • the spacer unit(s) (S) typically comprise
  • the tricyclodecane monomer may be characterized by the structures
  • the linking groups of the isocyanurate and tricyclodecane monomers are typically sufficiently low in molecular weight such that the monomer is a stable liquid at 25°C.
  • the linking group(s) is typically higher in molecular weight than the oxygen atom of for example 2,2-bis[4-(2-hydroxy-3- methacryloyloxypropoxy)phenyl]propane ("BisGMA"), a common monomer utilized in dental compositions, that links the (meth) aery late group to the aromatic ring.
  • the molecular weight of the linking group(s) of the monomers described is typically at least 50 g/mole or 100 g/mole. In some embodiments, the molecular weight of the linking group is at least 150 g/mole.
  • the molecular weight of the linking group is typically no greater than about 500 g/mole. In some embodiments, the molecular weight of the linking group is no greater than 400 g/mole or 300 g/mole.
  • the (i.e. calculated) molecular weight of the low shrink (e.g. isocyanurate and tricyclodecane) monomers is typically no greater than 2000 g/mole. In some embodiments, the molecular weight of the monomers is no greater than about 1500 g/mole or 1200 g/mole or 1000 g/mole. The molecular weight of the monomers is typically at least 600 g/mole.
  • the low shrink (e.g. isocyanurate and tricyclodecane) monomers is typically no greater than 2000 g/mole. In some embodiments, the molecular weight of the monomers is no greater than about 1500 g/mole or 1200 g/mole or 1000 g/mole. The molecular weight of the monomers is typically at least 600 g/mole.
  • the linking groups have one or more pendant substituents.
  • the linking groups may comprise one or more hydroxyl group substituents such an in the case of linking groups comprising alkoxy segments.
  • the linking groups are branched, and/or comprise at least one (i.e. aliphatic) cyclic moiety, and/or comprise at least one aromatic moiety.
  • a by-product is formed during the synthesis of the monomer that may be a solid at about 25°C (i.e. +/- 2 °C). Such by-product is typically removed from the liquid monomer.
  • the liquid monomer is substantially free of such solid fractions.
  • the liquid monomer may further comprise (e.g. non-crystalline) solid reaction by-products that are soluble in the liquid monomer.
  • the dental composition comprises a polymerizable compound having at least one cyclic allylic sulfide moiety with at least one (meth)acryloyl moiety.
  • a polymerizable compound is referred to herein as a hybrid monomer or a hybrid compound.
  • the cyclic allylic sulfide moiety typically comprises at least one 7- or 8-membered ring that has two heteroatoms in the ring, one of which is sulfur. Most typically both of the heteroatoms are sulfur, which may optionally be present as part of an SO, S0 2 , or S-S moiety.
  • the ring may comprise a sulfur atom plus a second, different heteroatom in the ring, such as oxygen or nitrogen.
  • the cyclic allylic moiety may comprise multiple ring structures, i.e. may have two or more cyclic allylic sulfide moieties.
  • the (meth)acryloyl moiety is preferably a (meth)acryloyloxy (i.e. a
  • the low shrinkage monomer includes those represented by the formulae:
  • each X can be independently selected from S, O, N, C (e.g., CH 2 or CRR, where each R is independently a H or an organic group), SO, SO 2 , N-alkyl, N-acyl, NH, N-aryl, carboxyl or carbonyl group, provided that at least one X is S or a group comprising S.
  • each X is S.
  • Y is either alkylene (e.g., methylene, ethylene, etc.) optionally including a heteroatom, carbonyl, or acyl; or is absent, thereby indicating the size of the ring, typically 7- to 10-membered rings, however larger rings are also contemplated.
  • the ring is either a 7- or 8-membered ring with Y thus being either absent or methylene, respectively.
  • Y is either absent or is a C 1 to C3 alkylene, optionally including a heteroatom, carbonyl, acyl, or combinations thereof.
  • Z is O, NH, N-alkyl (straight chain or branched), or N-aryl (phenyl or substituted phenyl).
  • the R' group represents a linker selected from alkylene (typically having more than one carbon atom, i.e. excluding methylene), alkylene optionally including a heteroatom (e.g., O, N, S, S-S, SO, S02), arylene, cycle-aliphatic, carbonyl, siloxane, amido (-CO-NH-), acyl (-CO-0-), urethane (-0-CO-NH-), and urea (-NH-CO-NH-) groups, and combinations thereof.
  • alkylene typically having more than one carbon atom, i.e. excluding methylene
  • alkylene optionally including a heteroatom (e.g., O, N, S, S-S, SO, S02), arylene, cycle-aliphatic, carbonyl, siloxane, amido (-CO-NH-), acyl (-CO-0-), urethane (-0-CO-NH-), and urea (-NH-CO-NH-)
  • R' comprises an alkylene group, typically a methylene or longer group, that may be either straight chain or branched, and which can be either unsubstituted, or substituted with aryl, cycloalkyl, halogen, nitrile, alkoxy, alkylamino, dialkylamino, akylthio, carbonyl, acyl, acyloxy, amido, urethane group, urea group, a cyclic allylic sulfide moiety, or combinations thereof.
  • alkylene group typically a methylene or longer group, that may be either straight chain or branched, and which can be either unsubstituted, or substituted with aryl, cycloalkyl, halogen, nitrile, alkoxy, alkylamino, dialkylamino, akylthio, carbonyl, acyl, acyloxy, amido, urethane group, urea group, a cyclic
  • R" is selected from H, and CH 3 , and "a" and “b” are independently 1 to 3.
  • the cyclic allylic sulfide moiety can further be substituted on the ring with one or more groups selected from straight or branched chain alkyl, aryl, cycloalkyl, halogen, nitrile, alkoxy, alkylamino, dialkylamino, akylthio, carbonyl, acyl, acyloxy, amido, urethane group, and urea group.
  • the selected substituents do not interfere with the hardening reaction.
  • Preferred are cyclic allylic sulfide structures that comprise unsubstituted methylene members.
  • a typical low shrinkage monomer can comprise an 8-membered cyclic allylic sulfide moiety with two sulfur atoms in the ring and with the linker attached directly to the 3 -position of the ring with an acyl group (i.e., Ring-OC(O)-).
  • MW weight average molecular weight
  • the weight average molecular weight (MW) of the hybrid monomer ranges from about 400 to about 900 and in some embodiments is at least 250, more typically at least 500, and most typically at least 800.
  • Representative polymerizable compounds having at least one cyclic allylic sulfide moiety with at least one (meth)acryloyl moiety include the following
  • a polymerizable compound having at least one cyclic allylic sulfide moiety can result in a synergistic combination of low volume shrinkage in combination with high diametral tensile strength.
  • the dental composition comprises a low shrinkage monomer that includes at lest one di-, tri-, and/or tetra (meth)acryloyl-containing materials having the general formula:
  • each X independently represents an oxygen atom (O) or a nitrogen atom (N);
  • m l to 5;
  • n 0 to 5;
  • p and q are independently 0 or 1 ;
  • this material is a derivative of bisphenol A
  • other low volume shrinkage monomer such as the isocyanurate and/or tricyclodecane monomer
  • the dental composition is free of (meth)acrylate monomers derived from bisphenol A.
  • the multifunctional low shrink monomers e.g. isocyanurate and tricyclodecane monomers are e.g. isocyanurate and tricyclodecane.
  • the viscosity as can be measured with a Haake RotoVisco RV1 device, as described in EP Application No. 10168240.9, filed July 02, 2010; is typically at least 300, or 400, or 500 Pa*s and no greater than 10,000 Pa*s. In some embodiments, the viscosity is no greater than 5000 or 2500 Pa*s.
  • the ethylenically unsaturated monomers of the dental composition are typically stable liquids at about 25°C meaning that the monomer do not substantially polymerize, crystallize, or otherwise solidify when stored at room temperature (about 25°C) for a typical shelf life of at least 30, 60, or 90 days.
  • the viscosity of the monomers typically does not change (e.g. increase) by more than 10% of the initial viscosity.
  • the ethylenically unsaturated monomers generally have a refractive index of at least 1.50. In some embodiments, the refractive index is at least 1.51, 1.52, 1.53, or greater.
  • the inclusion of sulfur atoms and/or the present of one or more aromatic moieties can raise the refractive index (relative to the same molecular weight monomer lacking such substituents).
  • the (unfilled) polymerizable resin may comprise solely one or more low shrink monomers in combination with the addition fragmentation agent(s).
  • the (unfilled) polymerizable resin comprises a small concentration of other monomer(s).
  • other is it meant an ethylenically unsaturated monomer such as a (meth) aery late monomer that is not a low volume shrinkage monomer.
  • concentration of such other monomer(s) is typically no greater than 20 wt-%, 19 wt-%, 18 wt-%, 17 wt-%, 16 wt-%, or 15 wt-% of the (unfilled) polymerizable resin portion.
  • the concentration of such other monomers is typically no greater than 5 wt-%, 4 wt-%, 3 wt-%, or 2 wt-% of the filled polymerizable dental composition.
  • the dental composition comprises a low viscosity reactive (i.e.
  • Reactive diluents typically have a viscosity as can be measured with a Haake RotoVisco RVl device, as described in EP Application No. 10168240.9, filed July 02, 2010, of no greater than 300 Pa*s and preferably no greater than 100 Pa*s , or 50 Pa*s, or 10 Pa*s. In some embodiments, the reactive diluent has a viscosity no greater than 1 or 0.5 Pa*s.
  • Reactive diluents are typically relatively low in molecular weight, having a molecular weight less than 600 g/mole, or 550 g/mol, or 500 g/mole.
  • Reactive diluents typically comprise one or two ethylenically unsaturated groups such as in the case of mono(meth)acrylate or di(meth)acrylate monomers.
  • the reactive diluent is an isocyanurate or tricyclodecane monomer.
  • Tricyclodecane reactive diluent may have the same generally structure as previously described. In favored embodiments, the tricyclodecane reactive diluent
  • One illustrative tricyclodecane reactive diluent has the general structure:
  • an addition fragmentation agent in a low volume shrinkage composition typically provides the lowest stress and/or lowest shrinkage
  • the addition fragmentation agents described herein can also reduce the stress and shrinkage of dental composition
  • conventional hardenable (meth)acrylate monomers such as ethoxylated bisphenol A dimethacrylate (BisEMA6), 2-hydroxyethyl methacrylate (HEMA), bisphenol A diglycidyl dimethacrylate (bisGMA), urethane dimethacrylate (UDMA), triethlyene glycol dimethacrylate (TEGDMA), glycerol dimethacrylate (GDMA), ethylenegylcol dimethacrylate, neopentylglycol dimethacrylate (NPGDMA), and
  • ethoxylated bisphenol A dimethacrylate BisEMA6
  • HEMA 2-hydroxyethyl methacrylate
  • bisGMA bisphenol A diglycidyl dimethacrylate
  • UDMA bisphenol A diglycid
  • PEGDMMA polyethyleneglycol dimethacrylate
  • the curable component of the curable dental composition can include a wide variety of other ethylenically unsaturated compounds (with or without acid functionality), epoxy-functional
  • the (e.g., photopolymerizable) dental compositions may include free radically polymerizable monomers, oligomers, and polymers having one or more ethylenically unsaturated groups. Suitable compounds contain at least one ethylenically unsaturated bond and are capable of undergoing addition polymerization. Examples of useful ethylenically unsaturated compounds include acrylic acid esters, methacrylic acid esters, hydroxy- functional acrylic acid esters, hydroxy-functional methacrylic acid esters, and combinations thereof.
  • Such free radically polymerizable compounds include mono-, di- or poly-(meth)acrylates (i.e., acrylates and methacrylates) such as, methyl (meth)acrylate, ethyl
  • (meth)acrylate isopropyl (meth)acrylate, n-hexyl (meth)acrylate, stearyl (meth)acrylate, allyl
  • (meth)acrylate bis[l-(2-acryloxy)]-p-ethoxyphenyldimethylmethane, bis[l-(3-acryloxy-2-hydroxy)]-p- propoxyphenyldimethylmethane, ethoxylated bisphenolA di(meth)acrylate, and trishydroxyethyl- isocyanurate tri(meth)acrylate;
  • (meth)acrylamides i.e., acrylamides and methacrylamides
  • (meth)acrylamides i.e., acrylamides and methacrylamides) such as (meth)acrylamide, methylene bis-(meth)acrylamide, and diacetone (meth)acrylamide
  • urethane urethane
  • (meth)acrylates the bis-(meth)acrylates of polyethylene glycols (preferably of molecular weight 200- 500); and vinyl compounds such as styrene, diallyl phthalate, divinyl succinate, divinyl adipate and divinyl phthalate.
  • vinyl compounds such as styrene, diallyl phthalate, divinyl succinate, divinyl adipate and divinyl phthalate.
  • Other suitable free radically polymerizable compounds include siloxane-functional (meth)acrylates. Mixtures of two or more free radically polymerizable compounds can be used if desired.
  • the curable dental composition may also contain a monomer having hydroxyl groups and ethylenically unsaturated groups in a single molecule.
  • hydroxyalkyl (meth)acrylates such as 2-hydroxyethyl (meth)acrylate and 2-hydroxypropyl (meth)acrylate
  • glycerol mono- or di-(meth)acrylate trimethylolpropane mono- or di-(meth)acrylate
  • bisGMA 2,2-bis[4-(2-hydroxy- 3-ethacryloxypropoxy)phenyl]propane
  • Suitable ethylenically unsaturated compounds are available from a wide variety of commercial sources, such as Sigma-Aldrich, St. Louis.
  • the dental compositions described herein may include one or more curable components in the form of ethylenically unsaturated compounds with acid functionality. Such components contain acidic groups and ethylenically unsaturated groups in a single molecule. When present, the polymerizable component optionally comprises an ethylenically unsaturated compound with acid functionality.
  • the acid functionality includes an oxyacid (i.e., an oxygen-containing acid) of carbon, sulfur, phosphorous, or boron.
  • an oxyacid i.e., an oxygen-containing acid
  • carbon sulfur, phosphorous, or boron.
  • ethylenically unsaturated compounds with acid functionality is meant to include monomers, oligomers, and polymers having ethylenic unsaturation and acid and/or acid-precursor functionality.
  • Acid-precursor functionalities include, for example, anhydrides, acid halides, and pyrophosphates.
  • the acid functionality can include carboxylic acid functionality, phosphoric acid functionality, phosphonic acid functionality, sulfonic acid functionality, or combinations thereof.
  • Ethylenically unsaturated compounds with acid functionality include, for example, ⁇ , ⁇ - unsaturated acidic compounds such as glycerol phosphate mono(meth)acrylates, glycerol phosphate di(meth)acrylates (GDMA-P), hydroxy ethyl (meth)acrylate (e.g., HEMA) phosphates,
  • ⁇ , ⁇ - unsaturated acidic compounds such as glycerol phosphate mono(meth)acrylates, glycerol phosphate di(meth)acrylates (GDMA-P), hydroxy ethyl (meth)acrylate (e.g., HEMA) phosphates,
  • the dental compositions can include an ethylenically unsaturated compound with acid
  • compositions are self-adhesive and are non-aqueous.
  • the curable dental compositions can include at least 1 wt-%, at least 3 wt-%, or at least 5 wt-% ethylenically unsaturated compounds with acid functionality, based on the total weight of the unfilled composition.
  • the compositions can include at most 80 wt-%, at most 70 wt-%, or at most 60 wt-% ethylenically unsaturated compounds with acid functionality.
  • a curable dental composition is described comprising at least 10 wt-% to about 30 wt-% of ethylenically unsaturated compounds with acid functionality, such as a mixture of HEMA and GDMA-P.
  • the curable dental compositions may include resin-modified glass ionomers cements such as those described in US patent Nos 5, 130,347 (Mitra) 5, 154,762 (Mitra) 5,962,550 (Akahane). Such compositions can be powder-liquid, paste-liquid or paste -paste systems. Alternatively, copolymer formulations such as those described in US patent No. 6, 126,922 (Rozzi) are included in the scope of the invention.
  • An initiator is typically added to the mixture of polymerizable ingredients.
  • the initiator is sufficiently miscible with the resin system to permit ready dissolution in (and discourage separation from) the polymerizable composition.
  • the initiator is present in the composition in effective amounts, such as from about 0.1 weight percent to about 5.0 weight percent, based on the total weight of the composition.
  • the addition-fragmentation agent is generally free-radically cleavable.
  • photopolymerization is one mechanism for generating free radicals, other curing mechanisms also generate free radicals.
  • the addition- fragmentation agent does not require irradiation with actinic radiation (e.g. photocuring) in order to provide the reduction in stress during curing.
  • the mixture of monomers is photopolymerizable and the composition contains a photoinitiator (i.e., a photoinitiator system) that upon irradiation with actinic radiation initiates the polymerization (or hardening) of the composition.
  • a photoinitiator i.e., a photoinitiator system
  • Such photopolymerizable compositions can be free radically polymerizable.
  • the photoinitiator typically has a functional wavelength range from about 250 nm to about 800 nm.
  • Suitable photoinitiators (i.e., photoinitiator systems that include one or more compounds) for polymerizing free radically photopolymerizable compositions include binary and tertiary systems.
  • Typical tertiary photoinitiators include an iodonium salt, a photosensitizer, and an electron donor compound as described in U.S. Pat. No. 5,545,676 (Palazzotto et al.).
  • Iodonium salts include diaryl iodonium salts, e.g., diphenyliodonium chloride, diphenyliodonium hexafluorophosphate, and
  • Some preferred photosensitizers may include monoketones and diketones (e.g. alpha diketones) that absorb some light within a range of about 300 nm to about 800 nm (preferably, about 400 nm to about 500 nm) such as camphorquinone, benzil, furil, 3,3,6,6- tetramethylcyclohexanedione, phenanthraquinone and other cyclic alpha diketones.
  • monoketones and diketones e.g. alpha diketones
  • diketones e.g. alpha diketones
  • camphorquinone is typically preferred.
  • Preferred electron donor compounds include substituted amines, e.g., ethyl 4-(N,N-dimethylamino)benzoate.
  • Suitable photoinitiators for polymerizing free radically photopolymerizable compositions include the class of phosphine oxides that typically have a functional wavelength range of about 380 nm to about 1200 nm.
  • Preferred phosphine oxide free radical initiators with a functional wavelength range of about 380 nm to about 450 nm are acyl and bisacyl phosphine oxides.
  • phosphine oxide photoinitiators capable of free-radical initiation when irradiated at wavelength ranges of greater than about 380 nm to about 450 nm include bis(2,4,6- trimethylbenzoyl)phenyl phosphine oxide (IRGACURE 819, Ciba Specialty Chemicals, Tarrytown, N.Y.), bis(2,6-dimethoxybenzoyl)-(2,4,4-trimethylpentyl) phosphine oxide (CGI 403, Ciba Specialty Chemicals), a 25:75 mixture, by weight, of bis(2,6-dimethoxybenzoyl)-2,4,4-trimethylpentyl phosphine oxide and 2- hydroxy-2-methyl- 1 -phenylpropan- 1 -one (IRGACURE 1700, Ciba Specialty Chemicals), a 1 : 1 mixture, by weight, of bis(2,4,6-trimethylbenzoyl)phenyl phos
  • Tertiary amine reducing agents may be used in combination with an acylphosphine oxide.
  • Illustrative tertiary amines include ethyl 4-(N,N-dimethylamino)benzoate and N,N-dimethylaminoethyl methacrylate.
  • the amine reducing agent is present in the photopolymerizable composition in an amount from about 0.1 weight percent to about 5.0 weight percent, based on the total weight of the composition.
  • the curable dental composition may be irradiated with ultraviolet (UV) rays.
  • suitable photoinitiators include those available under the trade designations IRGACURE and DAROCUR from Ciba Speciality Chemical Corp., Tarrytown, N.Y.
  • the photopolymerizable compositions are typically prepared by admixing the various components of the compositions.
  • the photoinitiator is combined under "safe light" conditions (i.e., conditions that do not cause premature hardening of the composition).
  • Suitable inert solvents may be employed if desired when preparing the mixture. Examples of suitable solvents include acetone and dichloromethane.
  • Hardening is affected by exposing the composition to a radiation source, preferably a visible light source.
  • a radiation source preferably a visible light source.
  • light sources that emit actinic radiation light between 250 nm and 800 nm (particularly blue light of a wavelength of 380-520 nm) such as quartz halogen lamps, tungsten- halogen lamps, mercury arcs, carbon arcs, low-, medium-, and high-pressure mercury lamps, plasma arcs, light emitting diodes, and lasers.
  • useful light sources have intensities in the range of 0.200- 1000 W/cm 2 .
  • a variety of conventional lights for hardening such compositions can be used.
  • the exposure may be accomplished in several ways.
  • the polymerizable composition may be continuously exposed to radiation throughout the entire hardening process (e.g., about 2 seconds to about 60 seconds). It is also possible to expose the composition to a single dose of radiation, and then remove the radiation source, thereby allowing polymerization to occur. In some cases materials can be subjected to light sources that ramp from low intensity to high intensity. Where dual exposures are employed, the intensity of each dosage may be the same or different. Similarly, the total energy of each exposure may be the same or different.
  • the dental compositions comprising the multifunctional ethylenically unsaturated monomers may be chemically hardenable, i.e., the compositions contain a chemical initiator (i.e., initiator system) that can polymerize, cure, or otherwise harden the composition without dependence on irradiation with actinic radiation.
  • a chemical initiator i.e., initiator system
  • Such chemically hardenable (e.g., polymerizable or curable) composition are sometimes referred to as "self-cure" compositions and may include redox cure systems, thermally curing systems and combinations thereof.
  • the polymerizable composition may comprise a combination of different initiators, at least one of which is suitable for initiating free radical polymerization.
  • the chemically hardenable compositions may include redox cure systems that include a polymerizable component (e.g., an ethylenically unsaturated polymerizable component) and redox agents that include an oxidizing agent and a reducing agent.
  • a polymerizable component e.g., an ethylenically unsaturated polymerizable component
  • redox agents that include an oxidizing agent and a reducing agent.
  • the reducing and oxidizing agents react with or otherwise cooperate with one another to produce free-radicals capable of initiating polymerization of the resin system (e.g., the ethylenically unsaturated component).
  • This type of cure is a dark reaction, that is, it is not dependent on the presence of light and can proceed in the absence of light.
  • the reducing and oxidizing agents are preferably sufficiently shelf- stable and free of undesirable colorization to permit their storage and use under typical conditions.
  • Useful reducing agents include ascorbic acid, ascorbic acid derivatives, and metal complexed ascorbic acid compounds as described in U.S. Pat. No.
  • amines especially tertiary amines, such as 4-tert-butyl dimethylaniline
  • aromatic sulfinic salts such as p-toluenesulfinic salts and benzenesulfinic salts
  • thioureas such as 1 -ethyl-2-thiourea, tetraethyl thiourea, tetramethyl thiourea, 1,1-dibutyl thiourea, and 1,3-dibutyl thiourea; and mixtures thereof.
  • secondary reducing agents may include cobalt (II) chloride, ferrous chloride, ferrous sulfate, hydrazine, hydroxylamine (depending on the choice of oxidizing agent), salts of a dithionite or sulfite anion, and mixtures thereof.
  • the reducing agent is an amine.
  • Suitable oxidizing agents will also be familiar to those skilled in the art, and include but are not limited to persulfuric acid and salts thereof, such as sodium, potassium, ammonium, cesium, and alkyl ammonium salts. Additional oxidizing agents include peroxides such as benzoyl peroxides,
  • hydroperoxides such as cumyl hydroperoxide, t-butyl hydroperoxide, and amyl hydroperoxide, as well as salts of transition metals such as cobalt (III) chloride and ferric chloride, cerium (IV) sulfate, perboric acid and salts thereof, permanganic acid and salts thereof, perphosphoric acid and salts thereof, and mixtures thereof.
  • transition metals such as cobalt (III) chloride and ferric chloride, cerium (IV) sulfate, perboric acid and salts thereof, permanganic acid and salts thereof, perphosphoric acid and salts thereof, and mixtures thereof.
  • oxidizing agent it may be desirable to use more than one oxidizing agent or more than one reducing agent. Small quantities of transition metal compounds may also be added to accelerate the rate of redox cure.
  • the reducing or oxidizing agents can be microencapsulated as described in U.S. Pat. No. 5,154,762 (Mitra et al.). This will generally enhance shelf stability of the polymerizable composition, and if necessary permit packaging the reducing and oxidizing agents together. For example, through appropriate selection of an encapsulant, the oxidizing and reducing agents can be combined with an acid- functional component and optional filler and kept in a storage-stable state.
  • Curable dental compositions can also be cured with a thermally or heat activated free radical initiator.
  • Typical thermal initiators include peroxides such as benzoyl peroxide and azo compounds such as azobisisobutyronitrile, as well as dicumyl peroxide, which is favored for mill blanks.
  • the dental composition typically comprises appreciable amounts of (e.g. nanoparticle) filler.
  • Such compositions preferably include at least 40 wt-%, more preferably at least 45 wt-%, and most preferably at least 50 wt-% filler, based on the total weight of the composition. In some embodiments the total amount of filler is at most 90 wt-%, preferably at most 80 wt-%, and more preferably at most 75 wt-% filler.
  • the (e.g. filled) dental composite materials typically exhibit a diametral tensile strength (DTS) of at least about 70, 75, or 80 MPa and/or a Barcol Hardness of at least about 60, or 65, or 70, or 75.
  • DTS diametral tensile strength
  • the depth of cure ranges from about 4 to about 5 and comparable to commercially available (e.g. filled) dental compositions suitable for restorations.
  • the compressive strength is at least 300, 325, 350 or 375 MPa.
  • the adhesion to enamel and/or dentin is at least 5, 6, 7, 8, 9, or lO MPa.
  • Dental compositions suitable for use as dental adhesives can optionally also include filler in an amount of at least 1 wt-%, 2 wt-%, 3 wt-%, 4 wt-%, or 5 wt-% based on the total weight of the composition.
  • the total concentration of filler is at most 40 wt-%, preferably at most 20 wt-%, and more preferably at most 15 wt-% filler, based on the total weight of the composition.
  • Fillers may be selected from one or more of a wide variety of materials suitable for incorporation in compositions used for dental applications, such as fillers currently used in dental restorative compositions, and the like.
  • the filler can be an inorganic material. It can also be a crosslinked organic material that is insoluble in the polymerizable resin, and is optionally filled with inorganic filler.
  • the filler is generally non-toxic and suitable for use in the mouth.
  • the filler can be radiopaque, radiolucent, or nonradiopaque. Fillers as used in dental applications are typically ceramic in nature.
  • Non-acid-reactive inorganic filler particles include quartz (i.e., silica), submicron silica, zirconia, submicron zirconia, and non- vitreous microparticles of the type described in U.S. Pat. No. 4,503, 169 (Randklev).
  • the filler can also be an acid-reactive filler.
  • Suitable acid-reactive fillers include metal oxides, glasses, and metal salts.
  • Typical metal oxides include barium oxide, calcium oxide, magnesium oxide, and zinc oxide.
  • Typical glasses include borate glasses, phosphate glasses, and fluoroaluminosilicate
  • the FAS glass typically contains sufficient elutable cations so that a hardened dental composition will form when the glass is mixed with the components of the hardenable composition.
  • the glass also typically contains sufficient elutable fluoride ions so that the hardened composition will have cariostatic properties.
  • the glass can be made from a melt containing fluoride, alumina, and other glass- forming ingredients using techniques familiar to those skilled in the FAS glassmaking art.
  • the FAS glass typically is in the form of particles that are sufficiently finely divided so that they can conveniently be mixed with the other cement components and will perform well when the resulting mixture is used in the mouth.
  • the average particle size (typically, diameter) for the FAS glass is no greater than 12 micrometers, typically no greater than 10 micrometers, and more typically no greater than 5 micrometers as measured using, for example, a sedimentation particle size analyzer.
  • Suitable FAS glasses will be familiar to those skilled in the art, and are available from a wide variety of commercial sources, and many are found in currently available glass ionomer cements such as those commercially available under the trade designations VITREMER, VITREBOND, RELY X LUTING CEMENT, RELY X LUTING PLUS CEMENT, PHOTAC-FIL QUICK, KETAC-MOLAR, and KETAC-FIL PLUS (3M ESPE Dental Products, St.
  • Nanofillers are also described in U.S. Pat. Nos. 7,090,721 (Craig et al.), 7,090,722 (Budd et al.) and 7, 156,91 1 ; and U.S. Patent No. 7,649,029 (Kolb et al.).
  • suitable organic filler particles include filled or unfilled pulverized polycarbonates, polyepoxides, poly(meth)acrylates and the like.
  • Commonly employed dental filler particles are quartz, submicron silica, and non- vitreous microparticles of the type described in U.S. Pat. No. 4,503, 169 (Randklev).
  • Mixtures of these fillers can also be used, as well as combination fillers made from organic and inorganic materials.
  • Fillers may be either particulate or fibrous in nature.
  • Particulate fillers may generally be defined as having a length to width ratio, or aspect ratio, of 20: 1 or less, and more commonly 10: 1 or less.
  • Fibers can be defined as having aspect ratios greater than 20: 1 , or more commonly greater than 100: 1.
  • the shape of the particles can vary, ranging from spherical to ellipsoidal, or more planar such as flakes or discs. The macroscopic properties can be highly dependent on the shape of the filler particles, in particular the uniformity of the shape.
  • Micron-size particles are very effective for improving post-cure wear properties.
  • nanoscopic fillers are commonly used as viscosity and thixotropy modifiers. Due to their small size, high surface area, and associated hydrogen bonding, these materials are known to assemble into aggregated networks.
  • the dental composition preferably comprise a nanoscopic particulate filler (i.e., a filler that comprises nanoparticles) having an average primary particle size of less than about 0.100 micrometers (i.e., microns), and more preferably less than 0.075 microns.
  • a nanoscopic particulate filler i.e., a filler that comprises nanoparticles
  • the average primary particle size of less than about 0.100 micrometers (i.e., microns), and more preferably less than 0.075 microns.
  • primary particle size refers to the size of a non-associated single particle.
  • the average primary particle size can be determined by cutting a thin sample of hardened dental composition and measuring the particle diameter of about 50-100 particles using a transmission electron micrograph at a magnification of 300,000 and calculating the average.
  • the filler can have a unimodal or polymodal (e.g., bimodal) particle size distribution.
  • the nanoscopic particulate material typically has an average primary particle size of at least about 2 nanometers (nm), and preferably at least about 7 nm.
  • the nanoscopic particulate material has an average primary particle size of no greater than about 50 nm, and more preferably no greater than about 20 nm in size.
  • the average surface area of such a filler is preferably at least about 20 square meters per gram (m 2 /g), more preferably, at least about 50 m 2 /g, and most preferably, at least about 100 m 2 /g.
  • the dental composition comprises silica nanoparticles.
  • Suitable nano-sized silicas are commercially available from Nalco Chemical Co. (Naperville, IL) under the product designation NALCO COLLOIDAL SILICAS.
  • preferred silica particles can be obtained from using NALCO products 1040, 1042, 1050, 1060, 2327 and 2329.
  • Silica particles are preferably made from an aqueous colloidal dispersion of silica (i.e., a sol or aquasol).
  • the colloidal silica is typically in the concentration of about 1 to 50 weight percent in the silica sol.
  • Colloidal silica sols that can be used are available commercially having different colloid sizes, see Surface & Colloid Science, Vol. 6, ed. Matijevic, E., Wiley Interscience, 1973.
  • Preferred silica sols for use making the fillers are supplied as a dispersion of amorphous silica in an aqueous medium (such as the Nalco colloidal silicas made by Nalco Chemical Company) and those which are low in sodium concentration and can be acidified by admixture with a suitable acid (e.g. Ludox colloidal silica made by E. I. Dupont de Nemours & Co. or Nalco 2326 from Nalco Chemical Co.).
  • a suitable acid e.g. Ludox colloidal silica made by E. I. Dupont de Nemours & Co. or Nalco 2326 from Nalco Chemical Co.
  • the silica particles in the sol have an average particle diameter of about 5- 100 nm, more preferably 10-50 nm, and most preferably 12-40 nm.
  • a particularly preferred silica sol is NALCO 1041.
  • the dental composition comprises zirconia nanoparticles.
  • Suitable nano-sized zirconia nanoparticles can be prepared using hydrothermal technology as described in U.S. Patent No. 7,241,437 (Davidson et al.).
  • lower refractive index (e.g. silica) nanoparticles are employed in combination with high refractive index (e.g. zirconia) nanoparticles in order to index match (refractive index within 0.02) the filler to the refractive index of the polymerizable resin.
  • high refractive index e.g. zirconia
  • the nanoparticles are in the form of nanoclusters, i.e. a group of two or more particles associated by relatively weak intermolecular forces that cause the particles to clump together, even when dispersed in a hardenable resin.
  • Preferred nanoclusters can comprise a substantially amorphous cluster of non-heavy (e.g. silica) particles, and amorphous heavy metal oxide (i.e. having an atomic number greater than 28) particles such as zirconia.
  • the particles of the nanocluster preferably have an average diameter of less than about 100 nm.
  • Suitable nanocluster fillers are described in U. S. Patent No. 6,730, 156 (Windisch et al.); incorporated herein by reference.
  • the dental composition comprises nanoparticles and/or nanoclusters surface treated with an organometallic coupling agent to enhance the bond between the filler and the resin.
  • the organometallic coupling agent may be functionalized with reactive curing groups, such as acrylates, methacrylates, vinyl groups and the like.
  • Suitable copolymerizable organometallic compounds may have the general formulas:
  • Preferred coupling agents include gamma-methacryloxypropyltrimethoxysilane, gamma-mercaptopropyltriethoxysilane, gamma- aminopropyltrimethoxysilane, and the like.
  • a combination of surface modifying agents can be useful, wherein at least one of the agents has a functional group co-polymerizable with a hardenable resin.
  • Other surface modifying agents which do not generally react with hardenable resins can be included to enhance dispersibility or rheological properties.
  • Examples of silanes of this type include, for example, aryl polyethers, alkyl, hydroxy alkyl, hydroxy aryl, or amino alkyl functional silanes.
  • the surface modification can be done either subsequent to mixing with the monomers or after mixing. It is typically preferred to combine the organosilane surface treatment compounds with nanoparticles before incorporation into the resin.
  • the required amount of surface modifier is dependant upon several factors such as particle size, particle type, modifier molecular wt, and modifier type. In general it is preferred that approximately a monolayer of modifier is attached to the surface of the particle.
  • the surface modified nanoparticles can be substantially fully condensed.
  • Fully condensed nanoparticles typically have a degree of crystallinity (measured as isolated metal oxide particles) greater than 55%, preferably greater than 60%, and more preferably greater than 70%.
  • the degree of crystallinity can range up to about 86% or greater.
  • the degree of crystallinity can be determined by X-ray diffraction techniques.
  • Condensed crystalline (e.g. zirconia) nanoparticles have a high refractive index whereas amorphous nanoparticles typically have a lower refractive index.
  • the dental compositions can have an initial color remarkably different than the cured dental structures. Color can be imparted to the composition through the use of a
  • photobleachable or thermochromic dye refers to loss of color upon exposure to actinic radiation.
  • the composition can include at least 0.001 wt-% photobleachable or thermochromic dye, and typically at least 0.002 wt-% photobleachable or thermochromic dye, based on the total weight of the composition.
  • the composition typically includes at most lwt-% photobleachable or thermochromic dye, and more typically at most 0.1 wt-% photobleachable or thermochromic dye, based on the total weight of the composition.
  • the amount of photobleachable and/or thermochromic dye may vary depending on its extinction coefficient, the ability of the human eye to discern the initial color, and the desired color change. Suitable thermochromic dyes are disclosed, for example, in U.S. Pat. No. 6,670,436 (Burgath et al.).
  • the photobleachable dye varies depending on a variety of factors including, for example, acid strength, dielectric constant, polarity, amount of oxygen, and moisture content in the atmosphere.
  • the bleaching properties of the dye can be readily determined by irradiating the composition and evaluating the change in color.
  • the photobleachable dye is generally at least partially soluble in a hardenable resin.
  • Photobleachable dyes include, for example, Rose Bengal, Methylene Violet, Methylene Blue, Fluorescein, Eosin Yellow, Eosin Y, Ethyl Eosin, Eosin bluish, Eosin B, Erythrosin B, Erythrosin Yellowish Blend, Toluidine Blue, 4',5'-Dibromofluorescein, and combinations thereof.
  • the color change can be initiated by actinic radiation such as provided by a dental curing light which emits visible or near infrared (IR) light for a sufficient amount of time.
  • actinic radiation such as provided by a dental curing light which emits visible or near infrared (IR) light for a sufficient amount of time.
  • the mechanism that initiates the color change in the compositions may be separate from or substantially simultaneous with the hardening mechanism that hardens the resin.
  • a composition may harden when polymerization is initiated chemically (e.g., redox initiation) or thermally, and the color change from an initial color to a final color may occur subsequent to the hardening process upon exposure to actinic radiation.
  • compositions may contain solvents (e.g., alcohols (e.g., propanol, ethanol), ketones
  • acetone e.g., acetone, methyl ethyl ketone
  • esters e.g., ethyl acetate
  • other nonaqueous solvents e.g., dimethylformamide, dimethylacetamide, dimethylsulfoxide, 1 -methyl-2-pyrrolidinone
  • compositions can contain additives such as indicators, dyes, pigments, inhibitors, accelerators, viscosity modifiers, wetting agents, buffering agents, radical and cationic stabilizers (for example BHT,), and other similar ingredients that will be apparent to those skilled in the art.
  • additives such as indicators, dyes, pigments, inhibitors, accelerators, viscosity modifiers, wetting agents, buffering agents, radical and cationic stabilizers (for example BHT,), and other similar ingredients that will be apparent to those skilled in the art.
  • medicaments or other therapeutic substances can be optionally added to the dental compositions.
  • examples include, but are not limited to, fluoride sources, whitening agents, anticaries agents (e.g., xylitol), calcium sources, phosphorus sources, remineralizing agents (e.g., calcium phosphate compounds), enzymes, breath fresheners, anesthetics, clotting agents, acid neutralizers, chemotherapeutic agents, immune response modifiers, thixotropes, polyols, anti-inflammatory agents, antimicrobial agents (in addition to the antimicrobial lipid component), antifungal agents, agents for treating xerostomia, desensitizers, and the like, of the type often used in dental compositions.
  • Combinations of any of the above additives may also be employed. The selection and amount of any one such additive can be selected by one of skill in the art to accomplish the desired result without undue experimentation.
  • the curable dental composition can be used to treat an oral surface such as tooth, as known in the art.
  • the compositions can be hardened by curing after applying the dental composition.
  • the method generally comprises applying the curable composition to an oral surface (e.g. cavity); and curing the composition.
  • a dental adhesive may be applied prior to application of the curable dental restoration material described herein.
  • Dental adhesives are also typically hardened by curing concurrently with curing the highly filled dental restoration composition.
  • the method of treating an oral surface may comprise providing a dental article and adhering the dental article to an oral (e.g. tooth) surface.
  • the compositions can be hardened (e.g., polymerized) into dental articles prior to applying.
  • a dental article such as a crown may be pre-formed from the hardenable dental composition described herein.
  • Dental composite (e.g. crowns) articles can be made from the curable composition described herein by casting the curable composition in contact with a mold and curing the composition.
  • dental composite (e.g. crowns) article can be made by first curing the composition forming a mill blank and then mechanically milling the composition into the desired article.
  • Another method of treating a tooth surface comprises providing a dental composition as described herein wherein the composition is in the form of a (partially hardened) hardenable, self-supporting, malleable structure having a first semi-finished shape; placing the hardenable dental composition on a tooth surface in the mouth of a subject; customizing the shape of the hardenable dental composition; and hardening the hardenable dental composition.
  • the customization can occur in the patient's mouth or on a model outside the patient mouth such as described in US 7,674,850 (Karim et al.); incorporated herein by reference.
  • 2-Isocyantoethyl methacrylate, l,2-epoxy-3-phenoxypropane, and 1 ,2-epoxydecane were obtained from TCI America (Portland, OR, USA).
  • Acryloyl chloride, triethyl amine, and triphenyl antimony were obtained from TCI America (Portland, OR, USA).
  • reaction was sampled, and 1H NMR analysis was consistent with the desired product as a mixture of isomers and indicated consumption of glycidyl methacrylate.
  • the reaction was cooled to room temperature to provide AFM-1 as a clear, very pale yellow viscous material.
  • the reaction was sealed with a plastic cap. With stirring, the mixture was heated to 100 °C in an oil bath.
  • Diacid 1 (2.50 g, 14.5 mmol) was added to the reaction in small portions over a period of 35 minutes.
  • a two-neck, 500 mL round-bottomed flask equipped with a magnetic stir bar was charged with AFM-1 (20.00 g, 43.81 mmol) and dichloromethane (160 mL).
  • the necks on the reaction flask were sealed with plastic caps and a 16 gauge needle was added to each cap to vent the reaction to air.
  • the reaction was cooled to 0 °C with stirring.
  • Triethylamine (30.5 mL, 22.1 g, 219 mmol) and 4- (dimethylamino)pyridine (1.609 g, 13.17 mmol) were added.
  • Methacryloyl chloride (17.0 ml, 18.4 g, 176 mmol) was added to the reaction mixture dropwise over a period of 40 minutes.
  • the pale yellow, heterogeneous reaction was allowed to slowly warm to room temperature. After 24 hours, the pale yellow reaction solution was concentrated in vacuo. Ethyl acetate (400 mL) was added to the residue and the mixture was transferred to a 1 L separatory funnel. The reaction flask was washed with aqueous hydrochloric acid (IN, 200 mL) and the aqueous hydrochloric acid solution was added to the separatory funnel. The solutions were mixed well and the aqueous layer was removed.
  • aqueous hydrochloric acid IN, 200 mL
  • the organic solution was further washed twice with 200 mL aqueous hydrochloric acid (IN), once with 200 mL of deionized water, three times with 200 mL of aqueous sodium hydroxide (IN), and once with 200 mL of a saturated aqueous solution of sodium chloride.
  • the organic solution was dried over sodium sulfate for 30 minutes and then filtered.
  • 2,6-di-t-butyl-4-methylphenol (0.01 1 g) was added, and the solution was concentrated in vacuo (bath temperature less than 20 °C) to a viscous solution.
  • the concentrated solution was transferred to an amber bottle using a small amount of dichloromethane to ensure quantitative transfer.
  • a three-neck, 250 mL round-bottomed flask was equipped with a magnetic stir bar.
  • Diol 2 (6.86 g, 14.52 mmol) was dissolved in dichloromethane (25 mL) and added to the reaction flask. Five additional 5mL portions of dichloromethane were used to ensure quantitative transfer of diol 2 and these rinses were added to the reaction flask.
  • the reaction flask was equipped with a pressure-equalizing addition funnel capped with a plastic cap. The other two necks on the reaction flask were also sealed with plastic caps, and a 16 gauge needle was added to each to vent the reaction to air. The reaction was cooled to 0 °C with stirring.
  • Triethylamine (10.0 mL, 7.26 g, 71.8 mmol) and 4-(dimethylamino)pyridine (0.532 g, 4.36 mmol) were added.
  • a 37.3 wt.% solution of methacryloyl chloride in toluene (16.28 g solution, 6.07 g methacryloyl chloride, 58.1 mmol) was added to the addition funnel.
  • the toluene solution of methacryloyl chloride was added to the reaction mixture dropwise over a period of 30 minutes. The reaction became pale yellow. After 18 hours, the pale yellow reaction solution was transferred to a 500 mL separatory funnel using dichloromethane (200 mL).
  • the organic solution was washed twice with 150 mL of aqueous hydrochloric acid (IN), once with 150 mL of deionized water, twice with 150 mL of aqueous sodium hydroxide (IN), and once with 200 mL of a saturated aqueous solution of sodium chloride.
  • the organic solution was dried over sodium sulfate for 30 minutes, and was then filtered and concentrated in vacuo (bath temperature less than 20 °C) to a viscous solution.
  • the concentrated solution was transferred to an amber bottle using a small amount of dichloromethane to ensure quantitative transfer. Air was bubbled through the viscous material to remove solvent.
  • 1H NMR analysis was consistent with the desired product as a mixture of isomers.
  • AFM-4 (8.463 g, 13.9 mmol, 96%) was obtained as a very viscous, pale yellow oil.
  • BisGMA (2,2-bis[4-(2-hydroxy-3-methacryloyloxypropoxy)phenyl]propane (Sigma Aldrich, St. Louis, MO)
  • TEGDMA triethyleneglycol dimethacrylate, Sartomer Co., Inc., Exton, PA
  • UDMA Diurethane dimethacrylate, CAS No. 41 137-60-4, commercially available as Rohamere 6661-0, Rohm Tech, Inc., Maiden, MA
  • BisEMA6 ethoxylated bisphenol A methacrylate as further described in U.S. Patent No. 6,030,606, available from Sartomer as "CD541"
  • CAPA2125 IEM refers to the reaction product of CAPA2125 (a polycaprolactone polyol available from Solvay Chemical Company, Warrington, UK) and two equivalents of 2-isocyanatoethyl methacrylate, prepared essentially as described in U.S. Patent No. 6,506,816)
  • GDMA-P 75 wt% glycerol dimethacrylate phosphate (prepared as described in J. Dent. Res., 35, 8466 (1956), may also be prepared as described in Example 2 of US 6,187,838) mixed with 25% wt%
  • EDMAB ethyl 4-(N,N-dimethylamino) benzoate, Sigma Aldrich
  • DPIHFP diphenyl iodonium hexafluorophosphate, Alpha Aesar, Ward Hill, MA
  • BZT refers to 2-(2-hydroxy-5-methacryloxyethylphenyl)-2H-benzotriazole, Ciba, Inc., Tarrytown, NY
  • Irgacure 819 phosphine oxide photoinitiator, available from Ciba Specialty Chemicals Corp., Tarrytown, NY
  • Zr/Si filler surface treated, one hundred parts zirconia silica filler of average particle size 0.6-0.9 micrometers was mixed with deionized water at a solution temperature of between 20-30°C, and the pH is adjusted to 3-3.3 with trifluoroacetic acid (0.278 parts).
  • A- 174 silane (SILQUEST A-174, gamma. - methacryloxypropyltrimethoxysilane, Crompton Corporation, Naugatuck, CT) was added to the slurry in an amount 7 parts and the blend is mixed over 2 hours. At the end of 2 hours, the pH is neutralized with calcium hydroxide. The filler is dried, crushed and screened through a 74 or 100 micron screen.)
  • Zr/Si Nano-Cluster Filler silane -treated zirconia/silica nanocluster filler prepared essentially as described in U.S. Patent No. 6,730,156 (Preparatory Example A (line 51-64) and Example B (column 25 line 65 through column 26 line 40))
  • silica filler silane -treated nano-sized silica having a nominal particle size of approximately 20 nanometers, prepared essentially as described in US Patent 6,572,693 B l, (column 21, lines 63-67 for Nanosized particle filler, Type #2)
  • Aerosil R812S (fumed silica, Degussa, Germany) Isocyanurate Trimer - Synthesis of Tri-HydroxyEthyl Iso Cyanurate Tris HEMA Phthalate
  • Phthalic acid anhydride (57.0 g, 0.385 mol, CAS # 85-33-9, Alfa Aesar, lot G30T004), 4- (dimethylamino)pyridine (DMAP, 4.9g, 0.04 mol, CAS # 1 122-58-3, Alfa Aesar, lot L125009), 2- hydoxyethylmethacrylate (HEMA, 50.9 g, 0.391 mol, and butylated hydroxytoluene (BHT, 0.140 g) were charged into a 2-liter 3 -neck reaction flask equipped with a mechanical stirrer, a thermocouple connected to a temperature controller, a dry air stream running through a T-shape connection into the reactor then to an oil bubbler, and a heating mantle.
  • DMAP dimethylamino)pyridine
  • HEMA 2- hydoxyethylmethacrylate
  • BHT butylated hydroxytoluene
  • the obtained solution was extracted with 200 ml of 1.0 N. HC1, 200 ml of 10% aqueous, 200 ml H 2 0, and 200 ml brine.
  • the organic layer was concentrated in a rotary evaporator with 40°C bath. Further drying was done under a vacuum pump at 50°C for 3 hours with air bleeding into the product during the whole time to give an almost colorless hazy viscous liquid. Refractive index was measured and found to be 1.5386.
  • NMR NMR
  • the calculated molecular weight of the linking group was determined to be 220 g/mole.
  • TCD alcohol and GMA as the corresponding epoxy functional reagent/s are mixed while stirring with e.g. cyclohexane.
  • 1.5 wt-% of TEA and 1.5 wt.-% of GAA (with respect to the mass of the sum of all reactants, to form in situ TEAA) 1000 ppm of HQ, 200 ppm of BHT, and 200 ppm of HQME are added while stirring.
  • the mixture is heated while stirring a temperature of about 70°C until completion of the addition reaction (measured via 1H-NMR: no signals of residual epoxy groups were detected).
  • 3 to 5 wt.-% of MSA is slowly added while stirring and stirring is continued for about 60 min at about 70°C.
  • the mixture is allowed to cool to room temperature while stirring.
  • the upper cyclohexane phase is separated from the oily viscous lower phase if existent.
  • the separated cyclohexane phase is washed once with water, then extracted twice with 2N NaOH solution, then once washed with water, then dried over anhydrous Na 2 SOzt. After filtration, the filtrate is again filtered through basic alumina. 100 ppm of BHT and 100 ppm of HQME are added to the filtrate. Then the solvent is stripped off in vacuum while air is bubbling through the crude sample.
  • TCD alcohol is diluted in anhydrous THF, then BF 3 *THF is added while stirring.
  • Gaseous EO is added while stirring so that the temperature of the reaction mixture does not exceed about 30-40°C.
  • 13 wt.-% of water (with respect to the sum of the amounts of the reactive educts) are added, after about 30 min while stirring 13 wt.-% of basic alumina is added, too.
  • 13 wt.-% of a solution of sodium methanolate in methanol (30% in methanol) is added. Then the suspension is stirred at room temperature for about 12 h. After filtration the solvent is stripped off in vacuum.
  • the slot was 8 mm long, 2.5 mm deep, and 2 mm across, and was located 2 mm from an edge, thus forming a 2 mm wide aluminum cusp adjacent to a 2 mm wide cavity containing dental compositions being tested.
  • a linear variable displacement transducer (Model GT 1000, used with an E309 analog amplifier, both from RDP Electronics, United Kingdom) was positioned as shown to measure the displacement of the cusp tip as the dental composition photocured at room temperature.
  • the slot in the aluminum block was sandblasted using Rocatec Plus Special Surface Coating Blasting Material (3M ESPE), treated with RelyX Ceramic Primer (3M ESPE), and finally treated with a dental adhesive, Adper Easy Bond (3M ESPE).
  • the slot was fully packed with the mixtures shown in the tables, which equalled approximately 100 mg of material.
  • the material was irradiated for 1 minute with a dental curing lamp (Elipar S-10, 3M ESPE) positioned almost in contact ( ⁇ 1 mm) with the material in the slot, then the displacement of the cusp in microns was recorded 9 minutes after the lamp was extinguished.
  • a dental curing lamp Elipar S-10, 3M ESPE
  • the Watts Shrinkage (Watts) Test Method measures shrinkage of a test sample in terms of volumetric change after curing.
  • the sample preparation (90-mg uncured composite test sample) and test procedure were carried out as described in the following reference: Determination of Polymerization Shrinkage Kinetics in Visible-Light-Cured Materials: Methods Development, Dental Materials, October 1991, pages 281-286. The results are reported as negative % shrinkage.
  • Diametral tensile strength of a test sample was measured according to the following procedure. An uncured composite sample was injected into a 4-mm (inside diameter) glass tube; the tube was capped with silicone rubber plugs. The tube was compressed axially at approximately 2.88 kg/cm 2 pressure for 5 minutes. The sample was then light cured for 80 seconds by exposure to a XL 1500 dental curing light (3M Company, St. Paul, MN), followed by irradiation for 90 seconds in a Kulzer UniXS curing box (Heraeus Kulzer GmbH, Germany). Cured samples were allowed to stand for 1 hour at about 37°C/90%+ Relative Humidity.
  • the sample was cut with a diamond saw to form disks about 2.2 mm thick, which were stored in distilled water at 37°C for about 24 hours prior to testing. Measurements were carried out on an Instron tester (Instron 4505, Instron Corp., Canton, MA) with a 10 kilonewton (kN) load cell at a crosshead speed of 1 mm/minute according to ISO Specification 7489 (or American Dental Association (ADA) Specification No. 27). Six disks of cured samples were prepared and measured with results reported in MPa as the average of the six measurements.
  • Barcol Hardness of a test sample was determined according to the following procedure. An uncured composite sample was cured in a 2.5-mm or 4-mm thick TEFLON mold sandwiched between a sheet of polyester (PET) film and a glass slide for 20 seconds and cured with an ELIPAR Freelight 2 dental curing light (3M Company). After irradiation, the PET film was removed and the hardness of the sample at both the top and the bottom of the mold was measured using a Barber-Coleman Impressor (a hand-held portable hardness tester; Model GYZJ 934- 1 ; Barber-Coleman Company, Industrial Instruments Division, Lovas Park, Ind.) equipped with an indenter. Top and bottom Barcol Hardness values were measured at 5 minutes after light exposure.
  • ELIPAR Freelight 2 dental curing light 3M Company
  • the depth of cure was determined by filling a 10 millimeter stainless steel mold cavity with the composite, covering the top and bottom of the mold with sheets of polyester film, pressing the sheets to provide a leveled composition surface, placing the filled mold on a white background surface, irradiating the dental composition for 20 seconds using a dental curing light (3M Dental Products Curing Light 2500or 3M ESPE Elipar FreeLight2, 3M ESPE Dental Products), separating the polyester films from each side of the mold, gently removing (by scraping) materials from the bottom of the sample (i.e., the side that was not irradiated with the dental curing light), and measuring the thickness of the remaining material in the mold.
  • the reported depths are the actual cured thickness in millimeters divided by 2.
  • a paste sample was extruded into a 2 mm X 2 mm X 25 mm quartz glass mold forming a test bar.
  • the material was then cured through the mold using 2 standard dental cure lights (3M ESPE XL2500 or 3M ESPE XL3000).
  • the samples were cured by placing one light in the center of the sample bar, curing for 20 sec, then simultaneously curing the ends of the bar for 20 sec, flipping and repeating.
  • the samples were stored submerged in distilled water at 37 deg. C prior to testing (16 to 24hrs).
  • Compressive strength of a test sample was measured according to the following procedure. An uncured composite sample was injected into a 4-mm (inside diameter) glass tube; the tube was capped with silicone rubber plugs; and then the tube was compressed axially at approximately 2.88 kg/cm 2 pressure for 5 minutes. The sample was then light cured for 80 seconds by exposure to a XL 1500 dental curing light (3M Company, St. Paul, MN), followed by irradiation for 90 seconds in a Kulzer UniXS curing box (Heraeus Kulzer GmbH, Germany). Cured samples were allowed to stand for 1 hour at about
  • Teeth Bovine incise teeth, free of soft tissue, were embedded in circular acrylic disks.
  • the embedded teeth were stored in water in a refrigerator prior to use.
  • the embedded teeth were ground to expose a flat enamel or dentin surface using 120-grit sandpaper mounted on a lapidary wheel. Further grinding and polishing of the tooth surface was done using 320-grit sandpaper on the lapidary wheel.
  • the teeth were continuously rinsed with water during the grinding process.
  • the polished teeth were stored in deionized water and used for testing within 2 hours after polishing.
  • the teeth were allowed to warm in a 36 deg. C oven to between room temperature (23 deg. C) and 36 deg. C before use.
  • Teeth Treatment A reinforcement label (having an opening 150 microns thick and 5 mm in diameter) was applied to the prepared tooth surfaces and a thin layer of the composite was applied with a dental applicator brush within the label opening, brushing for 20 sec. The composite layer was cured for 20 sec. using an Elipar S10 curing light (3M ESPE). Next, a teflon mold having an opening (2 mm thick by 5 mm diameter) was placed over the cured layer of composite, filled with more of the same composite, and the composite was cured for 20 sec. using the S 10 curing light. This formed a button of cured composite adhered to the prepared tooth surface.
  • 3M ESPE Elipar S10 curing light
  • Adhesive Bond Strength Testing The adhesive strength of a cured test example was evaluated by mounting the assembly (described above) in a holder clamped in the jaws of an INSTRON testing machine (Instron 4505, Instron Corp. Canton, Mass.) with the polished tooth surface oriented parallel to the direction of pull. A loop of orthodontic wire (0.44-mm diameter) was placed around the composite button adjacent to the polished tooth surface. The ends of the orthodontic wire were clamped in the pulling jaw of the INSTRON apparatus and pulled at a crosshead speed of 2 mm/min, thereby placing the adhesive bond in shear stress.
  • INSTRON testing machine Instron 4505, Instron Corp. Canton, Mass.
  • the test results show the improved properties of Examples 1 -20, comprising addition fragmentation materials, in comparison to CE1-CE5 that lack the inclusion of an addition fragmentation material. In particular, as the concentration of addition fragmentation materials, increased the compositions exhibits reduced stress and reduced Watts Shrinkage while maintaining sufficient Diametral tensile strength, Barcol hardness and depth of cure.
  • compositions were also prepared wherein an addition-fragmentation monomer was added to a conventional dental composition.
  • Compositions CE6 and 21 also contained 0.108 of DFIHFP and 0.03 of BHT.
  • test results are reported as follows. For each test the average is reported followed by the standard deviation in parenthesis. The number of samples utilized for each test is reported in the first row as "n”.
  • Compositions CE7-26 as follows, also contained 0.06 CPQ, 0.108 of DFIHFP, 0.216 EDMAB, 0.03 of BHT, 0.22 BZT, and 3.0 YbF3.
  • test results are reported as follows. For each test the average is reported followed by the standard deviation in parenthesis. The number of samples utilized for each test is reported in the first row as "n”.
  • the dental compositions comprising conventional dental monomers and addition fragmentation materials exhibited higher stress deflection results (e.g. > 2.0) than Examples 1 -20, comprising low shrinkage monomer and addition fragmentation materials.
  • the inclusion of an addition fragmentation material still substantially reduced the stress deflection in comparison to substantially the same composition lacking such addition fragmentation material.
  • ELIPAR XL 3000 curing light was used in place of the ELIPAR Freelight 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Dental Preparations (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)

Abstract

La présente invention concerne des compositions dentaires comprenant les éléments suivants : un agent de fragmentation d'addition comportant au moins un groupe terminal éthyléniquement insaturé et une unité de chaîne principale comportant un carbonyle α,β insaturé; au moins un monomère comportant au moins deux groupes éthyléniquement insaturés; et une matière de remplissage d'oxyde inorganique. Ledit agent de fragmentation d'addition est de préférence clivable par voie radicalaire libre. Ledit agent de fragmentation d'addition comprend de préférence au moins deux groupes terminaux éthyléniquement insaturés, tels que des groupes (méth)acrylates. Dans certains modes de réalisation, ledit agent de fragmentation d'addition présente la formule (I), dans laquelle R1, R2 et R3 sont chacun indépendamment Zm-Q-, un groupe (hétéro)alkyle ou un groupe (hétéro)aryle à la condition que R1 et/ou R2 et/ou R3 soit Zm-Q-; Q est un groupe de liaison possédant une valence de m + 1; Z est un groupe polymérisable éthyléniquement insaturé; m est compris entre 1 et 6; chaque X1 est indépendamment -O- ou -NR4-, R4 étant H ou C1-C4 alkyl; et n est 0 ou 1. L'invention porte en outre sur des articles dentaires préparés à partir d'une composition dentaire comprenant un agent de fragmentation d'addition, et sur des méthodes de traitement d'une surface dentaire.
PCT/US2012/024222 2011-02-15 2012-02-08 Compositions dentaires comprenant un agent de fragmentation d'addition éthyléniquement insaturé WO2012112350A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201280008646.3A CN103370041B (zh) 2011-02-15 2012-02-08 包含烯键式不饱和加成-断裂剂的牙科用组合物
JP2013553505A JP6077463B2 (ja) 2011-02-15 2012-02-08 エチレン性不飽和付加開裂剤を含む歯科用組成物
RU2013136505/15A RU2573997C2 (ru) 2011-02-15 2012-02-08 Стоматологические композиции, содержащие этиленненасыщенный агент присоединения-фрагментации
BR112013019702-1A BR112013019702B1 (pt) 2011-02-15 2012-02-08 Composições dentais compreendendo agente de adição-fragmentação etilenicamente insaturado.
US13/978,557 US9056043B2 (en) 2011-02-15 2012-02-08 Dental compositions comprising ethylenically unsaturated addition-fragmentation agent
EP15175714.3A EP2965742B1 (fr) 2011-02-15 2012-02-08 Compositions dentaires comprenant un agent d'addition-fragmentation éthyléniquement insaturé
EP12704603.5A EP2675422B1 (fr) 2011-02-15 2012-02-08 Compositions dentaires comprenant un agent de fragmentation d'addition éthyléniquement insaturé
US14/707,096 US9320685B2 (en) 2011-02-15 2015-05-08 Dental compositions comprising ethylenically unsaturated addition-fragmentation agent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161443218P 2011-02-15 2011-02-15
US61/443,218 2011-02-15
US201161521134P 2011-08-08 2011-08-08
US61/521,134 2011-08-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/978,557 A-371-Of-International US9056043B2 (en) 2011-02-15 2012-02-08 Dental compositions comprising ethylenically unsaturated addition-fragmentation agent
US14/707,096 Continuation US9320685B2 (en) 2011-02-15 2015-05-08 Dental compositions comprising ethylenically unsaturated addition-fragmentation agent

Publications (2)

Publication Number Publication Date
WO2012112350A2 true WO2012112350A2 (fr) 2012-08-23
WO2012112350A3 WO2012112350A3 (fr) 2012-12-27

Family

ID=45688265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/024222 WO2012112350A2 (fr) 2011-02-15 2012-02-08 Compositions dentaires comprenant un agent de fragmentation d'addition éthyléniquement insaturé

Country Status (7)

Country Link
US (2) US9056043B2 (fr)
EP (2) EP2675422B1 (fr)
JP (1) JP6077463B2 (fr)
CN (1) CN103370041B (fr)
BR (1) BR112013019702B1 (fr)
RU (1) RU2573997C2 (fr)
WO (1) WO2012112350A2 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013028401A1 (fr) * 2011-08-23 2013-02-28 3M Innovative Properties Company Agents d'addition-fragmentation
WO2014099317A1 (fr) * 2012-12-17 2014-06-26 3M Innovative Properties Company Oligomères d'addition-fragmentation
WO2014116461A1 (fr) 2013-01-24 2014-07-31 3M Innovative Properties Company Oligomérisation photo-initiée d'esters de méthacrylate
US9012531B2 (en) 2011-02-15 2015-04-21 3M Innovative Properties Company Dental compositions comprising mixture of isocyanurate monomer and tricyclodecane monomer
CN104781295A (zh) * 2012-11-12 2015-07-15 3M创新有限公司 加成-断裂剂
WO2015126657A1 (fr) * 2014-02-18 2015-08-27 3M Innovative Properties Company Oligomères d'addition-fragmentation ayant des groupes à indice de réfraction élevé
JP2016504278A (ja) * 2012-11-12 2016-02-12 スリーエム イノベイティブ プロパティズ カンパニー 付加開裂剤を含む歯科用組成物
WO2016069290A1 (fr) 2014-10-31 2016-05-06 3M Innovative Properties Company Materiaux dentaires et procédés
WO2016133668A1 (fr) * 2015-02-20 2016-08-25 3M Innovative Properties Company Oligomères d'addition-fragmentation
US9532929B2 (en) 2013-09-20 2017-01-03 3M Innovative Properties Company Trithiocarbonate-containing addition-fragmentation agents
WO2017136374A1 (fr) 2016-02-05 2017-08-10 3M Innovative Properties Company Compositions dentaires comprenant des nanoparticules produisant une différence d'indice de réfraction entre une résine polymérisable et une charge
US9758478B2 (en) 2013-10-16 2017-09-12 3M Innovative Properties Company Allyl disulfide-containing addition-fragmentation oligomers
US9907733B2 (en) 2011-08-23 2018-03-06 3M Innovative Properties Company Dental compositions comprising addition-fragmentation agents
US10350297B2 (en) 2014-10-31 2019-07-16 3M Innovative Properties Company Dental materials and methods
EP3622942A1 (fr) 2018-09-17 2020-03-18 Ivoclar Vivadent AG Matière polymère contenant des réactifs de transfert non saturés
WO2022096973A1 (fr) 2020-11-05 2022-05-12 3M Innovative Properties Company Agents d'addition-fragmentation d'imide
US11584817B2 (en) 2018-06-29 2023-02-21 3M Innovative Properties Company Orthodontic articles comprising cured free-radically polymerizable composition with improved strength in aqueous environment

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10370322B2 (en) 2011-02-15 2019-08-06 3M Innovative Properties Company Addition-fragmentation agents
US20120208965A1 (en) * 2011-02-15 2012-08-16 3M Innovative Properties Company Addition-fragmentation agents
JP6300899B2 (ja) * 2013-03-20 2018-03-28 スリーエム イノベイティブ プロパティズ カンパニー 高屈折率の付加−開裂剤
US10159548B2 (en) 2014-09-17 2018-12-25 Garrison Dental Solutions, L.L.C. Dental curing light
TWI515255B (zh) * 2014-12-31 2016-01-01 財團法人工業技術研究院 可固化樹脂及應用其之可固化組成物
EP3124009A1 (fr) * 2015-07-27 2017-02-01 DENTSPLY DETREY GmbH Adhésif dentaire
CN105107025B (zh) * 2015-09-11 2018-06-15 上海沪亮生物医药科技有限公司 一种有机/无机复合材料及其制备方法和在义齿制作中的用途
USD810293S1 (en) 2017-01-20 2018-02-13 Garrison Dental Solutions, Llc Dental instrument
KR101929652B1 (ko) 2017-03-20 2018-12-17 주식회사 케이씨씨 경화성 조성물
CN111225899B (zh) * 2017-12-05 2023-05-23 捷恩智株式会社 化合物、液晶组合物及液晶显示元件
WO2019111892A1 (fr) * 2017-12-06 2019-06-13 Jnc株式会社 Composé, composition de cristaux liquides, et élément d'affichage à cristaux liquides
EP3727276A2 (fr) 2017-12-21 2020-10-28 3M Innovative Properties Company Charges dentaires inorganiques comprenant une surface traitée au silane
WO2019211724A2 (fr) 2018-05-02 2019-11-07 3M Innovative Properties Company Composition adhésive dentaire en une partie pour fixer des matériaux composites dentaires
EP3610845A1 (fr) 2018-08-13 2020-02-19 Stick Tech OY Composition dentaire
DE102019122174A1 (de) 2019-08-19 2021-02-25 Voco Gmbh Dentale polymerisierbare Zusammensetzung auf der Basis kondensierter Silane
US20230119465A1 (en) * 2020-04-08 2023-04-20 3M Innovative Properties Company Curable compositions and methods of using the same
JP7515361B2 (ja) 2020-09-30 2024-07-12 株式会社松風 医科歯科用低重合収縮性モノマーの合成・製造方法
US20220153918A1 (en) * 2020-11-17 2022-05-19 Divergent Technologies, Inc. Isocyanurate resin compositions
EP4251117A1 (fr) 2020-11-25 2023-10-04 3M Innovative Properties Company Compositions dentaires durcissables et leurs utilisations
WO2022195364A1 (fr) 2021-03-17 2022-09-22 3M Innovative Properties Company 4,4'-spirobi[chromane]-2,2'-diones polymérisables et compositions durcissables les comprenant
CN118510482A (zh) * 2021-12-06 2024-08-16 舒万诺知识产权公司 牙科组合物
US20230210731A1 (en) * 2022-01-04 2023-07-06 Cao Group, Inc. Reduction resistant hydrogel thickeners
WO2023209463A1 (fr) 2022-04-26 2023-11-02 3M Innovative Properties Company Composition dentaire contenant un composant contenant une fraction résorcinol ou catéchol et son utilisation
WO2024121658A1 (fr) 2022-12-06 2024-06-13 Solventum Intellectual Properties Company Charge traitée en surface, composition dentaire contenant une telle charge, son procédé de production et son utilisation

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503169A (en) 1984-04-19 1985-03-05 Minnesota Mining And Manufacturing Company Radiopaque, low visual opacity dental composites containing non-vitreous microparticles
US4547323A (en) 1984-03-21 1985-10-15 Scm Corporation Synthesis of 2,2-dimethyl-4-methyleneglutaric acid and derivatives
US4886861A (en) 1985-04-23 1989-12-12 E. I. Dupont De Nemours And Company Molecular weight control in free radical polymerizations
US5130347A (en) 1987-12-30 1992-07-14 Minnesota Mining And Manufacturing Company Photocurable ionomer cement systems
US5154762A (en) 1991-05-31 1992-10-13 Minnesota Mining And Manufacturing Company Universal water-based medical and dental cement
US5324879A (en) 1985-12-03 1994-06-28 Commonwealth Scientific And Industrial Research Organisation Oligomerization process
US5501727A (en) 1994-02-28 1996-03-26 Minnesota Mining And Manufacturing Company Color stability of dental compositions containing metal complexed ascorbic acid
US5545676A (en) 1987-04-02 1996-08-13 Minnesota Mining And Manufacturing Company Ternary photoinitiator system for addition polymerization
US5962550A (en) 1997-03-19 1999-10-05 Gc Corporation Dental filling resin composition
US6030606A (en) 1998-06-22 2000-02-29 3M Innovative Properties Company Dental restoratives comprising Bis-EMA6
US6126922A (en) 1995-11-17 2000-10-03 3M Innovative Properties Company Fluorid-releasing compositions and compositions with improved rheology
US6187838B1 (en) 1997-01-13 2001-02-13 American Dental Association Health Foundation Polymerizable conditioners for adhesive bonding to dentin and enamel
WO2001030307A1 (fr) 1999-10-28 2001-05-03 3M Innovative Properties Company Materiaux dentaires constitues de nano-particules de silice
WO2001030305A1 (fr) 1999-10-28 2001-05-03 3M Innovative Properties Company Matieres dentaires radio-opaques constituees de nano-particules
US6284898B1 (en) 1997-03-25 2001-09-04 Ivoclar Ag Hydrolysable and polymerizable oxetane silanes
US6506816B1 (en) 1997-07-17 2003-01-14 3M Innovative Properties Company Dental resin cements having improved handling properties
US6572693B1 (en) 1999-10-28 2003-06-03 3M Innovative Properties Company Aesthetic dental materials
WO2003063804A1 (fr) 2002-01-31 2003-08-07 3M Innovative Properties Company Pates dentaires, articles dentaires, et procedes
US6670436B2 (en) 2001-02-12 2003-12-30 Ivoclar Vivadent Ag Thermochromic dental material
US6730156B1 (en) 1999-10-28 2004-05-04 3M Innovative Properties Company Clustered particle dental fillers
US6794520B1 (en) 1999-09-08 2004-09-21 Ivoclar Ag Hydrolyzable and polymerizable silanes based on methylene dithiepane
WO2006020760A1 (fr) 2004-08-11 2006-02-23 3M Innovative Properties Company Compositions auto-adhesives comprenant une pluralite de composes acides
US7090721B2 (en) 2004-05-17 2006-08-15 3M Innovative Properties Company Use of nanoparticles to adjust refractive index of dental compositions
US7090722B2 (en) 2004-05-17 2006-08-15 3M Innovative Properties Company Acid-reactive dental fillers, compositions, and methods
US7156911B2 (en) 2004-05-17 2007-01-02 3M Innovative Properties Company Dental compositions containing nanofillers and related methods
US7241437B2 (en) 2004-12-30 2007-07-10 3M Innovative Properties Company Zirconia particles
WO2008082881A1 (fr) 2006-12-28 2008-07-10 3M Innovative Properties Company Matériaux et compositions contenant du (méth)acryloyle, et procédés
US20080194722A1 (en) 2005-05-09 2008-08-14 Abuelyaman Ahmed S Dental Compositions Containing Hybrid Monomers
US7649029B2 (en) 2004-05-17 2010-01-19 3M Innovative Properties Company Dental compositions containing nanozirconia fillers
US7674850B2 (en) 2001-08-15 2010-03-09 3M Innovative Properties Company Hardenable self-supporting structures and methods
WO2011126647A2 (fr) 2010-03-31 2011-10-13 3M Innovative Properties Company Monomères d'isocyanurate polymérisables et compositions dentaires

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2318845A (en) * 1940-03-23 1943-05-11 Austenal Lab Inc Dental resin
US5444118A (en) * 1989-06-30 1995-08-22 Japan Synthetic Rubber Co., Ltd. Process for producing copolymer latex and paper coating composition, carpet backing composition or adhesive composition comprising said latex
US5264530A (en) * 1992-05-01 1993-11-23 E. I. Du Pont De Nemours And Company Process of polymerization in an aqueous system
US5770646A (en) * 1996-10-29 1998-06-23 E. I. Du Pont De Nemours And Company Aqueous branched polymer dispersant for hydrophobic materials
US6316519B1 (en) * 1997-02-19 2001-11-13 E. I. Du Pont De Nemours And Company Molecular weight controlled polymers by photopolymerization
US6174953B1 (en) * 1998-02-19 2001-01-16 E. I. Du Pont De Nemours And Company Low molecular weight (meth) acrylate copolymer emulsions
WO2000002939A1 (fr) * 1998-07-10 2000-01-20 E.I. Du Pont De Nemours And Company Micorgels et procedes de preparation associes
DE10042050A1 (de) * 2000-08-26 2002-03-14 Degussa Dentalkomposite aufweisend Hybridfüllstoffe und Verfahren zur Herstellung
US20060009574A1 (en) * 2001-01-26 2006-01-12 Aert Huub V Method of emulsion polymerization
AU2002253050A1 (en) * 2001-03-01 2002-10-15 Ciba Specialty Chemicals Holding Inc. Acid macromonomers and their method of preparation
JP2008535936A (ja) * 2005-02-10 2008-09-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド， ア ボディー コーポレイト 架橋ポリマーにおける応力緩和
US20080076848A1 (en) 2006-06-09 2008-03-27 Xiaoming Jin Low stress flowable compositions
CA2712236C (fr) 2008-01-15 2017-01-10 Dentsply International Inc. Composition de resine fonctionnelle pour une contrainte de polymerisation regulee
US8545222B2 (en) * 2008-10-21 2013-10-01 Chan Qian Wang Method of dental implant restoration
EP2401998A1 (fr) 2010-07-02 2012-01-04 3M Innovative Properties Company Composition dentaire, ensemble de pièces et leur utilisation
US20120208965A1 (en) 2011-02-15 2012-08-16 3M Innovative Properties Company Addition-fragmentation agents

Patent Citations (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547323A (en) 1984-03-21 1985-10-15 Scm Corporation Synthesis of 2,2-dimethyl-4-methyleneglutaric acid and derivatives
US4503169A (en) 1984-04-19 1985-03-05 Minnesota Mining And Manufacturing Company Radiopaque, low visual opacity dental composites containing non-vitreous microparticles
US4886861A (en) 1985-04-23 1989-12-12 E. I. Dupont De Nemours And Company Molecular weight control in free radical polymerizations
US5324879A (en) 1985-12-03 1994-06-28 Commonwealth Scientific And Industrial Research Organisation Oligomerization process
US5545676A (en) 1987-04-02 1996-08-13 Minnesota Mining And Manufacturing Company Ternary photoinitiator system for addition polymerization
US5130347A (en) 1987-12-30 1992-07-14 Minnesota Mining And Manufacturing Company Photocurable ionomer cement systems
US5154762A (en) 1991-05-31 1992-10-13 Minnesota Mining And Manufacturing Company Universal water-based medical and dental cement
US5501727A (en) 1994-02-28 1996-03-26 Minnesota Mining And Manufacturing Company Color stability of dental compositions containing metal complexed ascorbic acid
US6126922A (en) 1995-11-17 2000-10-03 3M Innovative Properties Company Fluorid-releasing compositions and compositions with improved rheology
US6187838B1 (en) 1997-01-13 2001-02-13 American Dental Association Health Foundation Polymerizable conditioners for adhesive bonding to dentin and enamel
US5962550A (en) 1997-03-19 1999-10-05 Gc Corporation Dental filling resin composition
US6284898B1 (en) 1997-03-25 2001-09-04 Ivoclar Ag Hydrolysable and polymerizable oxetane silanes
US6506816B1 (en) 1997-07-17 2003-01-14 3M Innovative Properties Company Dental resin cements having improved handling properties
US6030606A (en) 1998-06-22 2000-02-29 3M Innovative Properties Company Dental restoratives comprising Bis-EMA6
US6794520B1 (en) 1999-09-08 2004-09-21 Ivoclar Ag Hydrolyzable and polymerizable silanes based on methylene dithiepane
WO2001030307A1 (fr) 1999-10-28 2001-05-03 3M Innovative Properties Company Materiaux dentaires constitues de nano-particules de silice
US6387981B1 (en) 1999-10-28 2002-05-14 3M Innovative Properties Company Radiopaque dental materials with nano-sized particles
US6572693B1 (en) 1999-10-28 2003-06-03 3M Innovative Properties Company Aesthetic dental materials
US6730156B1 (en) 1999-10-28 2004-05-04 3M Innovative Properties Company Clustered particle dental fillers
WO2001030305A1 (fr) 1999-10-28 2001-05-03 3M Innovative Properties Company Matieres dentaires radio-opaques constituees de nano-particules
US6670436B2 (en) 2001-02-12 2003-12-30 Ivoclar Vivadent Ag Thermochromic dental material
US7674850B2 (en) 2001-08-15 2010-03-09 3M Innovative Properties Company Hardenable self-supporting structures and methods
US7393882B2 (en) 2002-01-31 2008-07-01 3M Innovative Properties Company Dental pastes, dental articles, and methods
WO2003063804A1 (fr) 2002-01-31 2003-08-07 3M Innovative Properties Company Pates dentaires, articles dentaires, et procedes
US7090721B2 (en) 2004-05-17 2006-08-15 3M Innovative Properties Company Use of nanoparticles to adjust refractive index of dental compositions
US7156911B2 (en) 2004-05-17 2007-01-02 3M Innovative Properties Company Dental compositions containing nanofillers and related methods
US7090722B2 (en) 2004-05-17 2006-08-15 3M Innovative Properties Company Acid-reactive dental fillers, compositions, and methods
US7649029B2 (en) 2004-05-17 2010-01-19 3M Innovative Properties Company Dental compositions containing nanozirconia fillers
WO2006020760A1 (fr) 2004-08-11 2006-02-23 3M Innovative Properties Company Compositions auto-adhesives comprenant une pluralite de composes acides
US7241437B2 (en) 2004-12-30 2007-07-10 3M Innovative Properties Company Zirconia particles
US20080194722A1 (en) 2005-05-09 2008-08-14 Abuelyaman Ahmed S Dental Compositions Containing Hybrid Monomers
WO2008082881A1 (fr) 2006-12-28 2008-07-10 3M Innovative Properties Company Matériaux et compositions contenant du (méth)acryloyle, et procédés
WO2011126647A2 (fr) 2010-03-31 2011-10-13 3M Innovative Properties Company Monomères d'isocyanurate polymérisables et compositions dentaires

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Determination of Polymerization Shrinkage Kinetics in Visible-Light-Cured Materials: Methods Development", DENTAL MATERIALS, October 1991 (1991-10-01), pages 281 - 286
HUTSON, L.; KRSTINA, J.; MOAD, G.; MORROW, G. R.; POSTMA, A.; RIZZARDO, E.; THANG, S. H., MACROMOLECULES, vol. 37, 2004, pages 4441 - 4452
J. DENT. RES., vol. 35, 1956, pages 8466
MATIJEVIC, E.: "Surface & Colloid Science", vol. 6, 1973, WILEY INTERSCIENCE
MOAD, C. L.; MOAD, G.; RIZZARDO, E.; THANG, S. H., MACROMOLECULES, vol. 29, 1996, pages 7717 - 7726
R. R. CARA ET AL., PARTICULATE SCIENCE AND TECHNOLOGY, vol. 28, 2010, pages 191 - 206

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012531B2 (en) 2011-02-15 2015-04-21 3M Innovative Properties Company Dental compositions comprising mixture of isocyanurate monomer and tricyclodecane monomer
WO2013028401A1 (fr) * 2011-08-23 2013-02-28 3M Innovative Properties Company Agents d'addition-fragmentation
US8980969B2 (en) 2011-08-23 2015-03-17 3M Innovative Properties Company Addition-fragmentation agents
US9907733B2 (en) 2011-08-23 2018-03-06 3M Innovative Properties Company Dental compositions comprising addition-fragmentation agents
KR102174015B1 (ko) * 2012-11-12 2020-11-04 쓰리엠 이노베이티브 프로퍼티즈 컴파니 부가-단편화제를 포함하는 치과용 조성물
CN104781295A (zh) * 2012-11-12 2015-07-15 3M创新有限公司 加成-断裂剂
JP2016504278A (ja) * 2012-11-12 2016-02-12 スリーエム イノベイティブ プロパティズ カンパニー 付加開裂剤を含む歯科用組成物
KR20200084925A (ko) * 2012-11-12 2020-07-13 쓰리엠 이노베이티브 프로퍼티즈 컴파니 부가-단편화제를 포함하는 치과용 조성물
US9414996B2 (en) 2012-11-12 2016-08-16 3M Innovative Properties Company Dental compositions comprising addition-fragmentation agents
US9410030B2 (en) 2012-11-12 2016-08-09 3M Innovative Properties Company Addition-fragmentation agents
KR20150096479A (ko) * 2012-12-17 2015-08-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 부가-단편화 올리고머
JP2016513071A (ja) * 2012-12-17 2016-05-12 スリーエム イノベイティブ プロパティズ カンパニー 付加開裂オリゴマー
CN104870484A (zh) * 2012-12-17 2015-08-26 3M创新有限公司 加成-断裂低聚物
US9463146B2 (en) 2012-12-17 2016-10-11 3M Innovative Properties Company Addition-fragmentation oligomers
KR102008353B1 (ko) 2012-12-17 2019-08-07 쓰리엠 이노베이티브 프로퍼티즈 컴파니 부가-단편화 올리고머
WO2014099317A1 (fr) * 2012-12-17 2014-06-26 3M Innovative Properties Company Oligomères d'addition-fragmentation
WO2014116461A1 (fr) 2013-01-24 2014-07-31 3M Innovative Properties Company Oligomérisation photo-initiée d'esters de méthacrylate
US9532929B2 (en) 2013-09-20 2017-01-03 3M Innovative Properties Company Trithiocarbonate-containing addition-fragmentation agents
US9758478B2 (en) 2013-10-16 2017-09-12 3M Innovative Properties Company Allyl disulfide-containing addition-fragmentation oligomers
WO2015126657A1 (fr) * 2014-02-18 2015-08-27 3M Innovative Properties Company Oligomères d'addition-fragmentation ayant des groupes à indice de réfraction élevé
US9730864B2 (en) 2014-02-18 2017-08-15 3M Innovative Properties Company Addition-fragmentation oligomers having high refractive index groups
JP2017515790A (ja) * 2014-02-18 2017-06-15 スリーエム イノベイティブ プロパティズ カンパニー 高屈折率基を有する付加開裂オリゴマー
US10350297B2 (en) 2014-10-31 2019-07-16 3M Innovative Properties Company Dental materials and methods
WO2016069290A1 (fr) 2014-10-31 2016-05-06 3M Innovative Properties Company Materiaux dentaires et procédés
US10479848B2 (en) 2015-02-20 2019-11-19 3M Innovative Properties Company Addition-fragmentation oligomers
WO2016133668A1 (fr) * 2015-02-20 2016-08-25 3M Innovative Properties Company Oligomères d'addition-fragmentation
US11111320B2 (en) 2015-02-20 2021-09-07 3M Innovative Properties Company Addition-fragmentation oligomers
WO2017136374A1 (fr) 2016-02-05 2017-08-10 3M Innovative Properties Company Compositions dentaires comprenant des nanoparticules produisant une différence d'indice de réfraction entre une résine polymérisable et une charge
US11246808B2 (en) 2016-02-05 2022-02-15 3M Innovative Properties Company Dental compositions comprising nanoparticles providing a refractive index differential between polymerizable resin and filler
US11584817B2 (en) 2018-06-29 2023-02-21 3M Innovative Properties Company Orthodontic articles comprising cured free-radically polymerizable composition with improved strength in aqueous environment
EP3622942A1 (fr) 2018-09-17 2020-03-18 Ivoclar Vivadent AG Matière polymère contenant des réactifs de transfert non saturés
WO2022096973A1 (fr) 2020-11-05 2022-05-12 3M Innovative Properties Company Agents d'addition-fragmentation d'imide

Also Published As

Publication number Publication date
US20150238389A1 (en) 2015-08-27
BR112013019702A2 (pt) 2017-10-24
JP6077463B2 (ja) 2017-02-08
EP2675422A2 (fr) 2013-12-25
RU2013136505A (ru) 2015-03-27
EP2965742A1 (fr) 2016-01-13
JP2014505105A (ja) 2014-02-27
BR112013019702B1 (pt) 2018-05-22
CN103370041B (zh) 2016-06-15
WO2012112350A3 (fr) 2012-12-27
US9056043B2 (en) 2015-06-16
US9320685B2 (en) 2016-04-26
US20130316307A1 (en) 2013-11-28
CN103370041A (zh) 2013-10-23
EP2965742B1 (fr) 2020-09-09
RU2573997C2 (ru) 2016-01-27
EP2675422B1 (fr) 2020-09-30

Similar Documents

Publication Publication Date Title
EP2675422B1 (fr) Compositions dentaires comprenant un agent de fragmentation d'addition éthyléniquement insaturé
US9012531B2 (en) Dental compositions comprising mixture of isocyanurate monomer and tricyclodecane monomer
EP2552380B1 (fr) Monomères d'isocyanurate polymérisables et compositions dentaires
US9168206B2 (en) Curable dental compositions and articles comprising polymerizable ionic liquids
EP2747737B1 (fr) Compositions dentaires contenant des agents d'addition-fragmentation
EP2916801B1 (fr) Compositions dentaires comprenant des agents de fragmentation d' addition
US10022306B2 (en) Dental compositions comprising a fatty mono(meth)acrylate
US9675529B2 (en) Dental composition containing high refractive index monomers
US8455565B2 (en) Disulfide monomers comprising ethylenically unsaturated groups suitable for dental compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12704603

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13978557

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2013553505

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012704603

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013136505

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013019702

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013019702

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130801

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载